ISC reaffirms its commitment to long-term shareholder value creation and disciplined capital allocation; responds to Plantro’s incorrect and flawed assertions Analysis demonstrates that ISC’s prudent and disciplined approach to growth and capital allocation has served all shareholders well, outperforming the S&P TSX Small Cap Index since the IPO in July 2013 ISC remains focused on performance, not provocation REGINA, Saskatchewan, May 12, 2025 (GLOBE NEWSWIRE) -- Information Services Corporation (TSX: ISC) (“ISC” or the “Company”) today released an investor presentation titled “A Proven Model for Value Creation”, which underscores the strength, stability and strategic vision that have defined ISC’s track record over more than a decade. The presentation is available here on the Company’s website. ISC has evolved into a diversified business with global scale, including a high-quality registry platform and a services segment delivering consistent, accretive growth. The Company’s registry operations remain anchored by a long-term exclusive contract in Saskatchewan until 2053, providing stable, CPI-linked cash flows for nearly 30 years. The Company’s disciplined M&A strategy has been supported entirely through balance sheet capacity. Since its IPO, ISC has: Significantly diversified its operations, which has led to nearly tripling its revenue and Adjusted EPS Executed against a proven and accretive M&A strategy that has delivered nearly $100 million in free cash flow generated by the Services segment since 2015 Achieved revenue compound annual growth rate (“CAGR”) growth of ~13.6 per cent since 2015 Provided a clear roadmap for continuing growth Delivered a total shareholder return (“TSR”) of 209 per cent, outperforming the S&P/TSX SmallCap Index since the IPO in July 2013 The Company remains committed to advancing a strategy grounded in stability, disciplined capital allocation and long-term shareholder value creation. To that end, ISC has released an investor presentation, available here on the Company’s website. ISC remains focused on performance, not provocation. The Company is resilient and diversified, with an experienced board and leadership team committed to executing a value-driven plan. ISC will continue to act in the best interests of all shareholders. PLANTRO’S CAMPAIGN OF MISINFORMATION AND COERCION ISC believes that offshore entity Plantro Ltd.’s (“Plantro”) repeated extensions to its unsolicited and undervalued Mini-tender offer (the “Mini-tender”) are a reflection of broad shareholder disinterest in the Mini-tender. ISC continues to recommend that shareholders Reject and Do Not Tender to Plantro’s undervalued Mini-Tender. The Company also fundamentally disagrees with Plantro’s assessment of the Company’s strategy, governance and value creation. Plantro’s presentation contains factual errors, several points and data that are selective and narrowly focused on building a particular narrative, and others that demonstrate a lack of understanding of the business, including ISC’s approach to M&A and its compensation and incentive programs. In light of continued mischaracterizations by Plantro, ISC urges shareholders to access accurate information through ISC’s public disclosure and filings available on ISC’s website at company.isc.ca and under ISC’s profile on SEDAR+ at www.sedarplus.ca. It is unfortunate that Plantro has pursued a path that undermined engagement from the outset. ISC is and has always demonstrated genuine interest in having constructive conversations with its shareholders and other stakeholders. Notwithstanding that Plantro did not engage at all with ISC, constructively or otherwise, ahead of its Mini-tender, the Company attempted to engage in good-faith dialogue with Plantro. ISC APPRECIATES BROAD SHAREHOLDER SUPPORT AMID DISTRACTIONS The Company wants to acknowledge and thank its many shareholders for their continued support; it is not something that is taken for granted. ISC has had, and continues to have, meaningful dialogue with all stakeholders as we look forward to the future success of the Company. Sifting through the noise and the distractions and being attentive to constructive and impactful suggestions will continue to improve the business and the returns to shareholders. Finally, and further to our focus on performance, the Company does not intend to continue a public dispute with either Plantro or Matthew Proud, unless it determines that disclosure is warranted due to further misinformation by Plantro or in accordance with the requirements of applicable securities law. Instead, and as always, ISC remains committed and prepared to engage with shareholders and interested investors who wish to have constructive and good faith dialogue with us. AdvisorsISC has engaged Kingsdale Advisors as its strategic shareholder and communications advisor, Stikeman Elliott LLP as legal advisor, and RBC Capital Markets as financial advisor. About ISC®Headquartered in Canada, ISC is a leading provider of registry and information management services for public data and records. Throughout our history, we have delivered value to our clients by providing solutions to manage, secure and administer information through our Registry Operations, Services and Technology Solutions segments. ISC is focused on sustaining its core business while pursuing new growth opportunities. The Class A Shares of ISC trade on the Toronto Stock Exchange under the symbol ISC. Cautionary Note Regarding Forward-Looking InformationThis news release contains forward-looking information within the meaning of applicable Canadian securities laws including, without limitation, statements related to ISC’s continuing growth, its strategy, its focus on performance, its commitment to executing a value-driven plan, acting in the best interests of shareholders, its interest in constructive conversations with stakeholders and its intentions in relation to Plantro Ltd. or Matthew Proud. Investor ContactJonathan HackshawSenior Director, Investor Relations & Capital MarketsToll Free: 1-855-341-8363 in North America or 1-306-798-1137investor.relations@isc.ca Media ContactAquin GeorgeKingsdale Advisors1-416-644-4031ageorge@kingsdaleadvisors.com The post ISC Releases Investor Presentation Highlighting A Proven Model for Value Creation appeared first on ForexTV.

Maintaining Momentum into Second Quarter 2025 and Remain on Track to Achieve Full Year 2025 Guidance Closed Maverick Acquisition Continuing to Execute our Strategy as the PDP Champion Returned Over $59 million to Shareholders Through Dividends and Repurchases Year to Date BIRMINGHAM, Ala., May 12, 2025 (GLOBE NEWSWIRE) -- Diversified Energy Company PLC (LSE: DEC, NYSE: DEC) is pleased to announce the following operations and trading update for the quarter ended March 31, 2025. **Consolidated operational & financial results for the quarter include only two weeks of Maverick Natural Resources (“Maverick”) contribution** Executing Strategic Objectives Closed transformational and accretive acquisition of Maverick Natural Resources Approximately doubling revenues and free cash flow Strengthened balance sheet and increased liquidity Credit facility borrowing base of $900 million with $451 million of current undrawn capacity and unrestricted cash; current leverage ratio of ~2.7x Retired $51 million of debt principal through amortizing debt payments during Q1 2025 Returned over $59 million year-to-date to shareholders through dividends and share repurchases(a) Declared 1Q25 dividend of $0.29 per share Repurchased ~1.5 million shares year-to-date in 2025, representing ~$19 million of share buybacks(a) Advantageously added natural gas hedge volumes in 2026 through 2029 during recent strength in forward curve On track to exceed $40 million in targeted land sales during the first half of 2025 Realized additional Coal Mine Methane (CMM) alternative energy credits with acquired assets from Summit Natural Resources Next LvL Energy collaborated with the State of West Virginia regulatory agencies to modernize well retirement procedures using a method that is environmentally sound, safe, and cost-effective Maverick Integration Full field level integration anticipated by the end of the second quarter with technology, and administrative integration anticipated by the end of the third quarter 2025 On track to exceed the annualized synergy target of over $50 million High-graded staffing and reduced redundancies to capture efficiencies and cost savings Contract savings providing impacts in compression and chemicals Delivering Reliable Results March 2025 exit rate of 1,149 MMcfepd (192 Mboepd)(b) Recorded average 1Q25 production of 864 MMcfepd (144 Mboepd) Total Revenue, inclusive of settled hedges, of $295 million Operating Cash Flow of $132 million, and Net loss of $337 million, inclusive of non-cash unsettled derivative adjustments Achieved 1Q25 Adjusted EBITDA(c) of $138 million and Free Cash Flow(d) of $62 million Realized 47% 1Q25 Adjusted EBITDA Margin(c) 1Q25 Total Revenue, Inclusive of Settled Hedges per Unit(e) of $3.78/Mcfe ($22.68/Boe) 1Q25 Adjusted Operating Cost per Unit(f) of $2.00/Mcfe ($12.01/Boe) Published the 5th annual Sustainability Report, “Winning Through Collaboration” Rusty Hutson, Jr., CEO of Diversified, commented: “Diversified is off to a great start in 2025, demonstrating the resilience of our business model in an otherwise volatile business environment while advancing our long-term strategy with the transformational acquisition of Maverick Natural Resources. Despite the broader macroeconomic and geopolitical challenges, we delivered solid operational results and continued growth in free cash flow. We remain committed to effectively allocating capital. Thus far this year, Diversified has returned over $59 million to our shareholders through dividends and share repurchases, while we continue to deleverage naturally from principal paydowns of our debt. We believe our shares remain a compelling investment at current levels, and we will continue to take advantage of the current cycle and market dislocation to opportunistically repurchase shares. At the same time, we have strategically invested in growing our business with our Maverick acquisition. We are highly focused on integration across all operations and functions of the organization, using the disciplined and methodical playbook we have historically executed to drive synergies and cost-saving initiatives that should provide margin expansion over time. We fully expect to exceed our annualized synergy target of $50 million. Despite the current uncertain environment, the Diversified team, with our ONE DEC culture, continues to perform at a high level. Diversified has a proven track record of managing through challenging markets. I am confident that with our highly strategic initiatives, we will capitalize on opportunities and emerge from the current market as an even stronger company, ensuring continued growth and success.” Operations and Finance Update Production The Company recorded exit rate production in March 2025 of 1,149 MMcfepd (192 Mboepd)(b) and delivered 1Q25 average net daily production of 864 MMcfepd (144 Mboepd). Net daily production for the quarter continued to benefit from Diversified’s peer-leading, shallow decline profile. The production for the quarter reflects the contribution of only two weeks of Maverick Natural Resources, which closed March 14th, 2025. Margin and Total Cash Expenses per Unit Diversified delivered 1Q25 per unit revenues of $3.78/Mcfe ($22.68/Boe) and Adjusted EBITDA Margin(a) of 47% (55% unhedged). Notably, these per unit metrics reflect an increase in both revenues and expenses from the incorporation of greater liquids-related production of Maverick Natural Resources. The Company’s per unit expenses are anticipated to improve as the Company implements its playbook to achieve long-term, sustainable synergies and cost savings. For example, General and Administrative expenses remained relatively consistent with prior period levels, despite the higher per unit costs of Maverick, supporting our progress on cost savings and synergy capture.   1Q25   1Q24       $/Mcfe   $/Boe   $/Mcfe   $/Boe   % Average Realized Price(1) $ 3.78   $ 22.68     $ 3.25   $ 19.50     16 %                       1Q25   1Q24     Adjusted Operating Cost per Unit(f) $/Mcfe   $/Boe   $/Mcfe   $/Boe   % Lease Operating Expense(2) $ 0.92   $ 5.49     $ 0.65   $ 3.91     40 % Midstream Expense $ 0.23   $ 1.40     $ 0.27   $ 1.61     (13 )% Gathering and Transportation $ 0.34   $ 2.06     $ 0.31   $ 1.85     11 % Production Taxes $ 0.21   $ 1.27     $ 0.12   $ 0.74     72 % Total Operating Expense(2) $ 1.70   $ 10.22     $ 1.35   $ 8.11     26 % Employees, Administrative Costs and Professional Fees(g) $ 0.30   $ 1.79     $ 0.33   $ 1.98     (10 )% Adjusted Operating Cost per Unit(f)(2) $ 2.00   $ 12.01     $ 1.68   $ 10.09     19 % Adjusted EBITDA Margin(a)   47 %     49 %     (1) 1Q25 excludes $0.04/Mcfe ($0.24/Boe) and 1Q24 excludes $0.05/Mcfe ($0.36/Boe) of other revenues generated by Next LVL Energy.(2) 1Q25 excludes $0.03/Mcfe ($0.22/Boe) and 1Q24 excludes $0.07/Mcfe ($0.39/Boe) of expenses attributable to Next LVL Energy.Values may not sum due to rounding. Opportunistic Layering of Additional Hedges at Premium Contract Prices Diversified has strategically taken advantage of the recent strength of the natural gas price curve to add to the Company’s 2026-2029 hedge portfolio and layering additional NYMEX volumes at an average floor price of ~$3.68/MMBtu, which is reflected in the financial derivatives positions as of April 30, 2025. Environmental Update Asset Retirement Progress and Next LVL Energy Update Next LvL Energy partnered with the State of West Virginia regulatory agencies to implement advanced testing protocols and improved technology to help modernize and upgrade well retirement procedures. Through the combined efforts of real-world situation testing and oversight, the State of West Virginia has enacted new asset retirement regulations, with the resulting framework achieving an environmentally sound, safe, and cost-effective methodology. Through the end of the first quarter, the Company has retired a combined 76 wells consisting of operated assets, state well retirements, and contracted retirement activity for third-party operators. Diversified is well-positioned to meet or exceed its retirement goal of 200 wells per year, with 57 operated wells retired as of March 31, 2025. The Company continues to drive stakeholder value via the realization of contractual partnerships to retire assets that eliminate orphaned or abandoned wells in our region and provide revenue to offset the cash costs associated with the retirement of Diversified’s wells. Combined Company 2025 Outlook The Company is reiterating its previously announced Full Year 2025 guidance. Following the recently completed acquisition of Maverick, Diversified expects to realize significant operational synergies associated with a larger, consolidated position in Oklahoma and the ability to improve the overall cost structure of the Maverick assets while continuing to prioritize returns and Free Cash Flow generation. The following outlook incorporates a nine-month contribution from the recently acquired Maverick assets.   2025 Guidance Total Production (Mmcfe/d) 1,050 to 1,100 % Liquids ~25% % Natural Gas ~75% Total Capital Expenditures (millions) $165 to $185 Adj. EBITDA(1) (millions) $825 to $875 Adj. Free Cash Flow(1) (millions) ~$420 Leverage Target 2.0x to 2.5x Combined Company Synergies (millions) >$50 (1) Includes the value of anticipated cash proceeds for 2025 land sales. Conference Call Details The Company will host a conference call today, Monday, May 12, 2025, at 1:00 PM GMT (8:00 AM EDT) to discuss the 1Q25 Trading Statement and will make an audio replay of the event available shortly thereafter. US (toll-free) +1 877 836 0271 UK (toll-free) +44 (0)800 756 3429 Web Audio https://www.div.energy/news-events/ir-calendarevents Replay Information https://ir.div.energy/financial-info     Footnotes: (a) Includes the total value of dividends paid and declared, and share repurchases (including Employee Benefit Trust) year-to-date, through May 12, 2025. (b) Exit rate includes full month of March 2025 production from Maverick. (c) Adjusted EBITDA represents earnings before interest, taxes, depletion, and amortization, and includes adjustments for items that are not comparable period-over-period; Adjusted EBITDA Margin represents Adjusted EBITDA as a percent of Total Revenue, Inclusive of Settled Hedges; For purposes of comparability, Adjusted EBITDA Margin excludes Other Revenue of $3 million in 1Q25 and $3 million in 1Q24, and Lease Operating Expense of $3 million in 1Q25 and $4 million in 1Q24 associated with Diversified’s wholly owned plugging subsidiary, Next LVL Energy; For more information, please refer to the Non-IFRS reconciliations as set out below. (d) Free Cash Flow represents net cash provided by operating activities less expenditures on natural gas and oil properties and equipment and cash paid for interest; For more information, please refer to the Non-IFRS reconciliations as set out below. (e) Includes the impact of derivatives settled in cash; For purposes of comparability, excludes certain amounts related to Diversified’s wholly owned plugging subsidiary, Next LVL Energy. (f) Adjusted Operating Cost represent total lease operating costs plus recurring administrative costs. Total lease operating costs include base lease operating expense, owned gathering and compression (midstream) expense, third-party gathering and transportation expense, and production taxes. Recurring administrative expenses (Adjusted G&A) is a Non-IFRS financial measure defined as total administrative expenses excluding non-recurring acquisition & integration costs and non-cash equity compensation; For purposes of comparability, excludes certain amounts related to Diversified’s wholly owned plugging subsidiary, Next LVL Energy. (g) As used herein, employees, administrative costs and professional services represent total administrative expenses excluding cost associated with acquisitions, other adjusting costs and non-cash expenses. We use employees, administrative costs and professional services because this measure excludes items that affect the comparability of results or that are not indicative of trends in the ongoing business.     For Company-specific items, refer also to the Glossary of Terms and/or Alternative Performance Measures found in the Company’s Annual Report and Form 20-F for the year ended December 31, 2024 filed with the United States Securities and Exchange Commission and available on the Company’s website. For further information, please contact: Diversified Energy Company PLC +1 973 856 2757 Doug Kris dkris@dgoc.com Senior Vice President, Investor Relations & Corporate Communications www.div.energy     FTI Consulting dec@fticonsulting.com U.S. & UK Financial Public Relations       About Diversified Energy Company PLC Diversified is a leading publicly traded energy company focused on natural gas and liquids production, transport, marketing, and well retirement. Through our unique differentiated strategy, we acquire existing, long-life assets and invest in them to improve environmental and operational performance until retiring those assets in a safe and environmentally secure manner. Recognized by ratings agencies and organizations for our sustainability leadership, this solutions-oriented, stewardship approach makes Diversified the Right Company at the Right Time to responsibly produce energy, deliver reliable free cash flow, and generate shareholder value. Forward-Looking Statements This announcement contains forward-looking statements (within the meaning of the U.S. Private Securities Litigation Reform Act of 1995) concerning the financial condition, results of operations, business and outlook of the Company and its wholly owned subsidiaries (the “Group”). All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements. These forward-looking statements, which contain the words “anticipate”, “believe”, “intend”, “estimate”, “expect”, “may”, “will”, “seek”, “continue”, “aim”, “target”, “projected”, “plan”, “goal”, “achieve”, “guidance” and words of similar meaning, reflect the Company’s beliefs and expectations and are based on numerous assumptions regarding the Company’s present and future business strategies and the environment the Company and the Group will operate in and are subject to risks and uncertainties that may cause actual results to differ materially. No representation is made that any of these statements or forecasts will come to pass or that any forecast results will be achieved. Forward-looking statements involve inherent known and unknown risks, uncertainties and contingencies because they relate to events and depend on circumstances that may or may not occur in the future and may cause the actual results, performance or achievements of the Company or the Group to be materially different from those expressed or implied by such forward looking statements. Many of these risks and uncertainties relate to factors that are beyond the Company’s or the Group’s ability to control or estimate precisely, such as future market conditions, currency fluctuations, the behavior of other market participants, the actions of regulators and other factors such as the Company’s or the Group’s ability to continue to obtain financing to meet its liquidity needs, the Company’s ability to successfully integrate acquisitions, including the acquired Maverick assets, changes in the political, social and regulatory framework, including inflation and changes resulting from actual or anticipated tariffs and trade policies, in which the Company or the Group operate or in economic or technological trends or conditions. The list above is not exhaustive and there are other factors that may cause the Company’s or the Group’s actual results to differ materially from the forward-looking statements contained in this announcement, Including the risk factors described in the “Risk Factors” section in the Company’s Annual Report and Form 20-F for the year ended December 31, 2024, filed with the United States Securities and Exchange Commission. Forward-looking statements speak only as of their date and neither the Company nor the Group nor any of its respective directors, officers, employees, agents, affiliates or advisers expressly disclaim any obligation to supplement, amend, update or revise any of the forward-looking statements made herein, except where it would be required to do so under applicable law. In light of these risks, uncertainties and assumptions, the events described in the forward-looking statements in this announcement, may not occur. As a result, you are cautioned not to place undue reliance on such forward-looking statements. Past performance of the Company cannot be relied on as a guide to future performance. No statement in this announcement is intended as a profit forecast or a profit estimate and no statement in this announcement should be interpreted to mean that the financial performance of the Company for the current or future financial years would necessarily match or exceed the historical published for the Company. Use of Non-IFRS Measures Certain key operating metrics that are not defined under IFRS (alternative performance measures) are included in this announcement. These non-IFRS measures are used by us to monitor the underlying business performance of the Company from period to period and to facilitate comparison with our peers. Since not all companies calculate these or other non-IFRS metrics in the same way, the manner in which we have chosen to calculate the non-IFRS metrics presented herein may not be compatible with similarly defined terms used by other companies. The non-IFRS metrics should not be considered in isolation of, or viewed as substitutes for, the financial information prepared in accordance with IFRS. Certain of the key operating metrics are based on information derived from our regularly maintained records and accounting and operating systems. Adjusted EBITDA As used herein, EBITDA represents earnings before interest, taxes, depletion, depreciation and amortization. Adjusted EBITDA includes adjusting for items that are not comparable period-over-period, namely, finance costs, accretion of asset retirement obligation, other (income) expense, loss on joint and working interest owners receivable, gain on bargain purchases, (gain) loss on fair value adjustments of unsettled financial instruments, (gain) loss on natural gas and oil property and equipment, costs associated with acquisitions, other adjusting costs, loss on early retirement of debt, non-cash equity compensation, (gain) loss on foreign currency hedge, net (gain) loss on interest rate swaps and items of a similar nature. Adjusted EBITDA should not be considered in isolation or as a substitute for operating profit or loss, net income or loss, or cash flows provided by operating, investing, and financing activities. However, we believe such a measure is useful to an investor in evaluating our financial performance because it (1) is widely used by investors in the natural gas and oil industry as an indicator of underlying business performance; (2) helps investors to more meaningfully evaluate and compare the results of our operations from period to period by removing the often-volatile revenue impact of changes in the fair value of derivative instruments prior to settlement; (3) is used in the calculation of a key metric in one of the financial covenants under our revolving credit facility; and (4) is used by us as a performance measure in determining executive compensation. When evaluating this measure, we believe investors also commonly find it useful to evaluate this metric as a percentage of our total revenue, inclusive of settled hedges, producing what we refer to as our adjusted EBITDA margin. The following table presents a reconciliation of the IFRS Financial measure of Net Income (Loss) to Adjusted EBITDA for each of the periods listed:   Three Months Ended Amounts in 000's March 31, 2025 March 31, 2024 December 31, 2024 Net income (loss) $ (337,391 ) $ (15,145 ) $ (102,033 ) Finance costs   42,820     27,416     37,453   Accretion of asset retirement obligation   10,353     7,183     8,323   Other (income) expense   (644 )   (5 )   (295 ) Income tax (benefit) expense   66,790     5,633     (125,052 ) Depreciation, depletion and amortisation   70,807     57,015     73,960   (Gain) loss on fair value adjustments of unsettled financial instruments   235,070     13,552     202,124   (Gain) loss on natural gas and oil property and equipment(1)   236     4     14,330   (Gain) loss on sale of equity interest   —     —     7,375   Unrealized (gain) loss on investment   —     —     6,446   Costs associated with acquisitions   2,885     1,519     4,532   Other adjusting costs(2)   5,963     3,693     7,644   Loss on early retirement of debt   39,485     —     2,469   Non-cash equity compensation   1,825     1,268     2,258   (Gain) loss on interest rate swap   (35 )   (50 )   (41 ) Total Adjustments $ 475,555   $ 117,228   $ 241,526   Adjusted EBITDA(c) $ 138,164   $ 102,083   $ 139,493   TTM Adjusted EBITDA $ 508,390   $ 497,510   $ 472,309   Pro Forma TTM Adjusted EBITDA(3) $ 952,216   $ 497,510   $ 548,570   (1) Excludes $2 million, $2 million and $8 million in cash proceeds received for leasehold sales during the three months ended March 31, 2025, March 31, 2024 and December 31, 2024, respectively.(2) Other adjusting costs for the three months ended December 31, 2024 were primarily associated with legal fees for certain litigation.(3) Pro forma TTM adjusted EBITDA includes adjustments for respective periods to pro forma results for the full twelve-month impact of intra-period acquisitions (March 31, 2025: Oaktree, Crescent Pass, East Texas II, Summit and Maverick; December 31, 2024: Oaktree, Crescent Pass Energy and East Texas II). Net Debt and Net Debt-to-Adjusted EBITDA As used herein, net debt represents total debt as recognized on the balance sheet less cash and restricted cash. Total debt includes our borrowings under our revolving credit facility and our borrowings under or issuances of, as applicable, our subsidiaries’ securitization facilities, excluding original issuance discounts and deferred finance costs. We believe net debt is a useful indicator of our leverage and capital structure. As used herein, net debt-to-adjusted EBITDA, or “leverage” or “leverage ratio,” is measured as net debt divided by adjusted trailing twelve-month EBITDA. We believe that this metric is a key measure of our financial liquidity and flexibility and is used in the calculation of a key metric in one of the financial covenants under our revolving credit facility. The following table presents a reconciliation of the IFRS Financial measure of Total Non-Current Borrowings to the Non-IFRS measure of Net Debt and a calculation of Net Debt-to-Adjusted EBITDA and Net Debt-to-Pro Forma Adjusted EBITDA for each of the periods listed:   As of Amounts in 000's March 31, 2025 March 31, 2024 December 31, 2024 Total non-current borrowings, net $ 2,544,937   $ 1,066,643   $ 1,483,779   Current portion of long-term debt   156,253     184,463     209,463   LESS: Cash   (32,641 )   (3,456 )   (5,990 ) LESS: Restricted cash   (106,011 )   (32,828 )   (46,269 ) Net Debt $ 2,562,538   $ 1,214,822   $ 1,640,983   Pro forma TTM adjusted EBITDA(1) $ 952,216   $ 497,510   $ 548,570   Net debt-to-pro forma TTM adjusted EBITDA 2.7x 2.4x 3.0x (1) Pro forma TTM adjusted EBITDA includes adjustments for respective periods to pro forma results for the full twelve-month impact of intra-period acquisitions (March 31, 2025: Oaktree, Crescent Pass, East Texas II, Summit and Maverick; December 31, 2024: Oaktree, Crescent Pass Energy and East Texas II). Free Cash Flow As used herein, free cash flow represents net cash provided by operating activities less expenditures on natural gas and oil properties and equipment and cash paid for interest. We believe that free cash flow is a useful indicator of our ability to generate cash that is available for activities other than capital expenditures. The Directors believe that free cash flow provides investors with an important perspective on the cash available to service debt obligations, make strategic acquisitions and investments, and pay dividends. The following table presents a reconciliation of the IFRS Financial measure of Net Cash from Operating Activities to the Non-IFRS measure of Free Cash Flow for each of the periods listed: Amounts in 000'sExcept per share amounts Three Months Ended Three Months Ended Twelve Months Ended March 31, 2025 March 31, 2024 March 31, 2025 Net cash provided by operating activities $ 131,539   $ 106,258   $ 370,944   LESS: Expenditures on natural gas and oil properties and equipment   (28,031 )   (9,293 )   (70,838 ) LESS: Cash paid for interest   (41,574 )   (23,759 )   (140,956 ) Free Cash Flow(d) $ 61,934   $ 73,206   $ 159,150   Total Revenue, Inclusive of Settled Hedges and Adjusted EBITDA Margin As used herein, total revenue, inclusive of settled hedges, includes the impact of derivatives settled in cash. We believe that total revenue, inclusive of settled hedges, is a useful measure because it enables investors to discern our realized revenue after adjusting for the settlement of derivative contracts. The following table presents a reconciliation of the IFRS Financial measure of Total Revenue to the Non-IFRS measure of Total Revenue, Inclusive of Settled Hedges and a calculation of Adjusted EBITDA Margin for each of the periods listed: Amounts in 000's Three Months Ended Three Months Ended Year Ended March 31, 2025 March 31, 2024 December 31, 2024 Total revenue 346,903   193,624   794,841   Net gain (loss) on commodity derivative instruments(1) (52,271 ) 22,066   151,289   Total revenue, inclusive of settled hedges(c) 294,632   215,690   946,130   Adjusted EBITDA(c) 138,164   102,083   472,309   Adjusted EBITDA Margin(c) 47 % 47 % 50 % Adjusted EBITDA Margin, exclusive of Next LVL Energy(2) 47 % 49 % 51 % (1) Net gain (loss) on commodity derivative settlements represents cash (paid) or received on commodity derivative contracts. This excludes settlements on foreign currency and interest rate derivatives as well as the gain (loss) on fair value adjustments for unsettled financial instruments for each of the periods presented.(2) For purposes of comparability, Adjusted EBITDA Margin excludes Other Revenue of $3 million in 1Q25 and $3 million in 1Q24, and Lease Operating Expense of $3 million in 1Q25 and $4 million in 1Q24 associated with Diversified’s wholly owned plugging subsidiary, Next LVL Energy. The post Diversified Energy Reports Strong First Quarter 2025 Results Driven by Increased Top-Line Revenue Generation and Operational Discipline appeared first on ForexTV.

         PRESS RELEASE AB SCIENCE PRESENTS ITS FINANCIAL INFORMATION AS OF DECEMBER 31, 2024 AND THE KEY EVENTS OF THE PERIOD Financial and corporate situation Operating deficit of 6,1 million euros as of December 31, 2024, down 55% compared to December 31, 2023 Cash position of 8,0 million euros as of December 31, 2024 Clinical development Masitinib platform: Update on the development of masitinib in progressive forms of multiple sclerosis following the ECTRIMS 2024 conference Positive results from the phase 2 study of masitinib in Covid-19 Update on the EMA's decision concerning the application for conditional marketing authorization for masitinib in the treatment of amyotrophic lateral sclerosis Health Canada re-examination procedure Update on the confirmatory programme for neurodegenerative diseases Strengthening the intellectual property of masitinib in mastocytosis Strengthening the intellectual property of masitinib in sickle cell disease Microtubule platform: Update on the AB8939 microtubule program and in in particular on the ability of AB8939 to generate a response on MECOM rearrangement Paris, May 12, 2025, 8am CET AB Science SA (Euronext - FR0010557264 - AB) today reports its revenues for the year 2024 and provides an update on its activities. CLINICAL DEVELOPMENT KEY EVENTS DURING THE YEAR 2024 AND SINCE DECEMBER 31, 2024 Update on the AB8939 microtubule program and in particular on the ability of AB8939 to generate a response on MECOM rearrangement AB Science provided an update on the microtubule program AB8939. AB8939 is a next-generation synthetic microtubule destabiliser and ALDH1/2 inhibitor targeting stem cells with key differentiating factors for the treatment of relapsed/refractory acute myeloid leukaemia (AML). Animal experiments have demonstrated the relevant properties of AB8939 to the treatment of AML The objective of the Phase 1 study is to determine the maximum tolerated dose (MTD) for three different cycles of AB8939. The first stage of Phase 1 was completed with 28 patients enrolled, assessing the maximum tolerated dose after 3 consecutive days of treatment with AB8939. The second stage of phase 1 was nearing completion by 31 December 2024, assessing the maximum tolerated dose after 14 consecutive days of treatment with AB8939. The next step is to assess the maximum tolerated dose after 14 consecutive days of treatment with AB8939 in combination with either venetoclax or azacitidine and in combination with venetoclax plus azacitidine, both of which are widely used in AML and for which AB8939 has shown an additive effect. The MECOM gene is associated with a poor prognosis, with almost all patients dying within 12 months of relapse. AB8939 is an ALDH-targeted stem cell therapy with potential use in AML with MECOM. AB8939 has shown activity against the MECOM gene rearrangement, based on non-clinical and early clinical data, with an observed response rate of 50%. The next steps in clinical development will be discussed with the FDA and the EMA. The first objective is to develop AB8939 in patients suffering from AML with the MECOM gene. The second objective is to position AB8939 in broader forms of AML. The intellectual property rights of AB8939 in AML are guaranteed until 2036 through a ‘composition of matter’ patent and potentially until 2044 in AML with chromosomal abnormalities, including the MECOM gene, through a ‘second medical use’ patent. AB Science is the sole owner of AB8939 and its family of compounds. Update on the development of masitinib in progressive forms of multiple sclerosis following the ECTRIMS 2024 conference AB Science provided an update on the development of masitinib in progressive forms of multiple sclerosis (MS), following the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2024 conference. The development of masitinib in progressive forms of multiple sclerosis is based on the MAXIMS study (AB20009), a randomized, double-blind, phase 3 study of masitinib 4.5 mg/kg/day in patients with primary progressive multiple sclerosis (PPMS) and non-active secondary progressive multiple sclerosis (nSPMS). The recent results of tolebrutinib in non-active secondary progressive MS presented at the ECTRIMS 2024 conference, reinforce the scientific hypothesis that targeting microglia in nSPMS is a valid approach. Tolebrutinib belongs to a class of drugs that target microglia through an enzymatic target called BTK (Bruton Tyrosine Kinase). Masitinib also targets microglia but through a different enzymatic target called M-CSFR1 (Macrophage Colony Stimulating Factor Receptor-1) and generated positive results in phase 2B (AB07002), which are consistent with BTK data. EDSS progression confirmed at 3 months was reduced by 37% with masitinib in study AB07002 and by 23% with tolebrutinib in the Hercules study (although the reduction in study AB07002 did not reach the conventional 5% p-value since the study was not powered to detect a significant effect in this secondary endpoint, having 300 patients in the masitinib 4.5 or placebo arms as compared with 1100 patients in the Hercules trial). EDSS progression confirmed at 6 months was reduced by 32% with masitinib and by 31% with tolebrutinib. Importantly, Masitinib significantly improved manual dexterity measured by 9-hole Peg test, in study AB07002 (-4,28 ; p=0,0388). Masitinib has shown the ability to decrease serum neurofilament light chain (NfL) concentration in an animal model of MS, and by extension therefore, possibly neuronal damage. Masitinib not only targets microglia but also mast cells, which play a crucial role in progressive MS and in the experimental autoimmune encephalomyelitis (EAE) model of MS, as shown by numerous publications. Masitinib benefits from a large safety database with long-term exposure across various indications. In non-oncology indications, around 2,200 patients have received at least one dose of masitinib, more than 1,300 patients have received masitinib for more than six months and close to 1,000 patients have received masitinib for more than one year. As a conclusion, masitinib represents a potential credible alternative to BTK inhibitors in the development of new drugs both in primary and non-active secondary progressive MS. Positive results from the phase 2 study of masitinib in Covid-19 AB Science announced the results of a Phase 2 study evaluating masitinib in COVID-19. This Phase 2 study (AB20001) was designed to evaluate the safety and efficacy of masitinib plus isoquercetin in hospitalized patients with moderate COVID-19 (WHO 7-point ordinal scale level 4) or severe COVID-19 (level 5). The study initially planned to recruit 200 patients (over 18 years of age with no upper age limit). The primary objective was to improve the clinical status of patients after 15 days of treatment, as measured by the WHO 7-point ordinal scale. Following a DSMB recommendation, decision was taken to continue the study only in level 4 patients (i.e. hospitalized patients with oxygen supply <6 L/min with SpO2 maintained ≥92%). The study could not recruit the planned 200 patients. The decision was therefore taken to stop inclusion after 95 patients were randomized. The objective was to detect a trending treatment effect with 95 patients that would translate into a significant effect when simulating the same effect with the planned enrolment of 200 patients. If this objective was reached, then the conclusion would be that it is worth continuing to evaluate masitinib as an agent in the treatment of covid in patients hospitalized with moderate need of oxygen. The study showed an odds ratio of 2.4 in favor of the treatment arm after 15 days of treatment, superior to the odds ratio of 2.2 initially hypothesized, with p=0.038 simulated with 200 patients and p=0.072 detected with 95 patients recruited. Sensitivity analyses at day 12, 13 and 14 with 95 patients recruited displayed a p-value of respectively p=0.016, 0.019, 0.018 and odds ratio 3.2, 3.2 and 3.4. This was due to improvement of certain placebo patients at day 15 but not before. The safety was in line with the known safety profile of masitinib. Update on the EMA's decision concerning the application for conditional marketing authorization for masitinib in the treatment of amyotrophic lateral sclerosis Health Canada re-examination procedure AB Science announced that the European Medicines Agency (EMA) confirmed a negative opinion for the conditional marketing authorization of masitinib in the treatment of amyotrophic lateral sclerosis (ALS), following a vote adopted during the Committee for Medicinal Products for Human Use (CHMP) meeting on 14-17 October 2024. The Conditional Marketing Authorization of masitinib had been under review by the CHMP in response to the company’s request for a re-examination of the negative opinion issued in June 2024. Separately, Health Canada recently informed AB Science that key analyses presented for the reconsideration submitted in May 2024 [1], have been considered as new data, rather than re-analyses of existing data. Considering that Health Canada guideline prevent the use of new data as part of the re-examination procedure, AB Science has decided to notify Health Canada it will not pursue the reconsideration. Health Canada has offered the possibility to submit a new application to resolve this issue. Update on the confirmatory programme for neurodegenerative diseases AB Science provided an update on the masitinib platform by indication. Amyotrophic lateral sclerosis: A new confirmatory study AB23005, which simplifies patient recruitment and targets the best responders to masitinib, will be launched in accordance with FDA and EMA recommendations. The study design has been approved by the FDA and the EMA. The confirmatory study has been approved by the FDA. The first AB10015 study generated a strong hypothesis in patients with normal progression and before any loss of function, with a significant survival of +12 months. Long-term follow-up showed that 53% of patients survived beyond 5 years, with a benefit of +36 months compared with the ENCALS prediction. Some patients have survived between 10 and 15 years and continue to receive treatment. Progressive forms of multiple sclerosis. The mechanism of action targeting microglia reinforced after the success of a BTK inhibitor which also targets microglia. Targeting mast cells adds to the efficacy since mast cells activate microglia and directly acts on myelin degradation. Masitinib Hazard Ratio of EDSS progression compared with BTK inhibitor Hazard Ratio published shows that masitinib is competitive, even if the populations are not comparable and the comparison is indirect. Alzheimer's disease. Targeting the innate immune reaction stands out in addition to main strategy with biologics aimed at reducing beta amyloid or Tau protein plaques. Masitinib is the only drug that generated positive results in moderate Alzheimer’s Disease. Masitinib could be combined with biologics in early and mild Alzheimer’s Disease. More generally, the failure of multiple programs for decades reinforces the value of masitinib approach to target the innate immune reaction through modulation of microglia and mast cells. The unmet medical need in those three indications is immense. The markets are huge with potential sales exceeding billions in each indication. Masitinib IP rights are secured through use patent until 2037 in ALS and up to 2041 in MS and AD, and by orphan drug status in ALS and data protection of 10 years in Europe and 8 years in the USA. Strengthening the intellectual property of masitinib in mastocytosis AB Science announced that the European Patent Office has issued a Notice of Allowance for a patent relating to methods of treating severe systemic mastocytosis (i.e. a medical use patent) with masitinib. This new European patent provides intellectual property protection for masitinib in this indication until October 2036. The same medical use patent strategy has been successfully applied in amyotrophic lateral sclerosis, with a worldwide patent granted until 2037, and is being applied in other indications such as multiple sclerosis, Alzheimer's disease for protection until 2041, and in prostate cancer for protection until 2042. Strengthening the intellectual property of masitinib in sickle cell disease AB Science announced that the United States Patent Office has issued a Notice of Allowance for a method patent (i.e. a medical use patent) for the treatment of sickle cell disease with its lead compound, masitinib, based on preclinical results. This new US patent protects masitinib's intellectual property in this indication until November 2040, and further strengthens masitinib's intellectual property, following a Notice of Allowance received from the European Patent Office in October 2024 for the same patent. CONSOLIDATED FINANCIAL INFORMATION FOR THE YEAR 2024 The operating result as of December 31, 2024 was a loss of 6,083 thousand euros, compared to a loss of 13,429 thousand euros as of December 31, 2023, representing a reduction in the operating deficit of 7,346 thousand euros (55%). Operating income consists exclusively of revenue related to the exploitation of a veterinary medicine. Revenue was 10% higher than at 31 December 2023, at 1,072 thousand euros at 31 December 2024 compared with 970 thousand euros a year earlier. Operating expenses decreased by 50%, or 7,244 thousand euros, between the years ended 31 December 2024 and 2023. This change in the 2024 financial year is attributable to the following factors: Cost of sales of 176 thousand euros, mainly due to the effect of changes in inventories relating to the reconstitution of AB8939 product inventories for phase 1 in progress. A 39.5% decrease in marketing expenses (206 thousand euros), reflecting ongoing efforts to control costs. A 62% (6,541 thousand euros) reduction in research and development costs, reflecting ongoing efforts to control costs and seeking of partnerships. Net financial income amounted to a loss of 1,749 thousand euros for the year ended 31 December 2024, compared with income of 1,444 thousand euros for the year ended 31 December 2023. Other financial income amounted to 469 thousand euros, mainly relating to : The change in the fair value of the warrants attached to the EIB loan: a gain of 143 thousand euros The change in the fair value of the ADPEs: a gain of 57 thousand euros Income of 269 thousand euros from the extinguishment of a lease liability (IFRS 16) in connection with the early termination of a contract. Other financial expenses amounted to 994 thousand euros in 2023 compared with 107 thousand euros in 2024, the decrease being mainly due to the reversal of the fair value of the ‘share conversion option’ component of the bond issue, which generated an expense of 969 thousand euros. As a reminder, at 31 December 2023 other financial income of 1,670 thousand euros related mainly to : The difference between the derecognition of the ADPC debt following their cancellation for 3,692 thousand euros and the recognition of the new E shares, created to replace the ADPCs and with a value of 2,908 thousand euros. This transaction generated net income of 784 thousand euros The change in fair value of the warrants attached to the EIB loan: a gain of 285 thousand euros The change in the fair value of the ADPEs: a gain of 421 thousand euros. These effects have no impact on cash flow. The consolidated net loss as of 31 December 2023 is 7,831 thousand euros compared to a loss of 11,985 thousand euros as of 31 December 2023, a decrease of 35%. The following table summarizes the consolidated financial statements for the year 2024 prepared in accordance with IFRS, and comparative information with the year 2023: In thousands of euros, except for share data 31/12/2024 31/12/2023 Net turnover 1,072 970 Cost of sales and marketing expenses 176 (383) Marketing expenses (316) (522) Administrative expenses (3,079) (3,017) Research and development expenses (3,936) (10,477) Operating income (6,083) (13,429) Financial income 678 4,993 Financial expenses (2,427) (3,549) Financial income (1,749) 1,444 Net income (7,831) (11,985) Other comprehensive income for the period net of tax (7,809) (11,729) Total comprehensive income for the period (0.15)  (0.24) Basic earnings per share - in euros (0.15)  (0.24) Diluted earnings per share - in euros 1,072 970 In thousands of euros 31/12/2024 31/12/2023 Cash and cash equivalents 7,987 6,066 Total assets 23,175 25,499 Equity (23,754) (21,010) Non-current liabilities 26,496 27,825 Trade payables 10,028 11,075 Current liabilities 20,433 18,683 OTHER CORPORATE INFORMATION FOR YEAR 2024 AND SINCE DECEMBER 31, 2024 Capital increase by private placement for an amount of 5 million euros AB Science has announced a capital increase of 5.0 million euros through the issue of 5,368,725 new ordinary shares, each of which is attached to share subscription warrants. This capital increase was subscribed by qualified European investors. The Capital Increase consisted of a private placement pursuant to Articles L. 225-136 of the French Commercial Code and L. 411-2 1° of the French Monetary and Financial Code and has been carried out with a waiver of preferential subscription rights, pursuant to the delegation of authority granted to the Board of Directors under the 19th resolution of the Combined General Shareholders’ Meeting of June 26, 2024. The Capital Increase has taken the form of the issuance of 5,368,725 new ordinary shares (the “New Shares”) to each of which are attached a share subscription warrant (the “Warrants”). Two tranches of New Shares have been issued: for the first tranche of 4,294,980 New Shares, two Warrants give right to the subscription of one ordinary share; for the second tranche of 1,073,745 New Shares, three Warrants give right to the subscription of one ordinary share. The Capital Increase is made through a cash contribution of 5.0 million euros. All of the 5,368,725 New Shares and all of the 2,505,405 new shares that would be issued upon exercise of the warrants, i.e. a total of 7,874,130 shares in the Company, represent 13.3% of the Company's current share capital. The issue price of the New Shares has been set at 0.93132 euro (0.01 euro par value and 0,92132 euro of issue premium) and the exercise price of the Warrants at 1.16415 euro, representing a total fundraising of 5.0 million euros (taking into account the exercise of the warrants, the maximum amount of the Capital Increase could be increased to a total amount of 7.9 million euros). The issue price of the New Shares has been calculated based on the volume-weighed average price of AB Science shares over the last three trading days (on Euronext Paris) preceding the price calculation, with a 10% discount. The Warrants may be exercised from November 26, 2026 to December 31, 2028, will be immediately detached from the New Shares upon their issuance and will not be listed. AB Science completed the settlement and delivery of this capital increase. The proceeds of the Capital Increase will provide AB Science with the additional resources necessary to finance its activities over the next twelve months. Subscription by Alpha Blue Ocean of a tranche of one million shares within the framework of the Term Capital Increase Program (PACTTM) The PACT TM program entered into with Alpha Blue Ocean (ABO) was renewed on April 28, 2023 for a period of 24 months. The Board of Directors of AB Science decided to draw down one million shares under this program, on the basis of the 17th resolution of the combined general meeting of shareholders of June 30, 2023 (reserved cash capital increase with waiver of preferential subscription rights). They were subscribed by Alpha Blue Ocean at the end of March 2024 at a price of 2.5701 euros (i.e. the volume-weighted average price of AB Science's shares on Euronext Paris during the three trading sessions preceding the drawdown request). AB Science received the entire proceeds from the issue of the shares subscribed by Alpha Blue Ocean, and 80% of these proceeds were placed in an escrow account. Alpha Blue Ocean is now responsible for selling, in an orderly manner, the subscribed AB Science shares. During the first half of 2024, 377,393 shares were placed. 95% of the sale proceeds (reduced by a structuring fee equal to 3% of the issue price) is paid monthly to AB Science, directly by Alpha Blue Ocean or by drawing on the escrow account referred to above, after deduction of the 20% deposit of the issue proceeds retained by AB Science. In total, over the first half of 2024, these disposals resulted in payments by ABO, net of commission, of 682,181 euros (including the 20% of the issue proceeds initially retained by AB Science). The IFRS accounting treatment of the PACT TM program is detailed in note 13 of the appendix to the half-yearly accounts (impact on equity and debts, cash receipts, amount of the escrow account as of June 30). Coverage initiation by DNA Finance and In Extenso Finance AB Science announced that two financial analysis firms, DNA Finance and In Extenso Finance, have initiated the coverage of the Company. DNA Finance estimates that AB Science stands out as a compelling investment opportunity in the biotech sector. In Extenso has initiated a strong buy opinion on the share. These new coverages aim to strengthen the AB Science visibility among French and international institutional investors and to broaden its investor base. They are in addition to the coverage by Chardan, an investment bank based in the United States and specialized in biotechnologies and health technologies. Partial payments of 2020, 2021 and 2022 research tax credit by the tax administration in 2024, for a total amount of 7,913 thousand euros Confirmation by the Paris Court of Appeal of the acquittal of the CEO of AB Science, Alain Moussy, and reduction of the amount of the financial penalty imposed on AB Science AB Science and the Chairman of the French market regulator (Autorité des Marchés Financiers - AMF) had filed an appeal to the Paris Court of Appeal against the decision of the AMF Sanctions commission, dated March 24, 2022, which acquitted Alain Moussy, CEO of AB Science, for an alleged insider trading and sanctioned AB Science for a failure to comply with some of its communication obligations (as part of the assessment of conditions for a deferral of privileged information publication), as indicated in the AB Science press release of March 29, 2022. The Paris Court of Appeal confirmed the fully acquittal of Alain Moussy and reduced by 200,000 euros the amount of the financial penalty pronounced against AB Science. This amount of 200,000 euros will have to be reimbursed by the French Treasury, as AB Science has paid the full financial penalty initially pronounced by the AMF Sanctions commission on March 24, 2022. Transactions involving securities The balance of 262,704 category C preference shares (the “ADPC”) was repurchased for a symbolic euro by AB Science with a view to their cancellation, in application of the financial restructuring agreement signed on April 21, 2023. During 2024, the following securities were subscribed: 7,722,8993 share warrants, including 5,368,725 warrants as part of the capital increase in September 2024, which may give rise to the creation of 2,505,405 54,000 new shares, including 1,558,953 warrants exercisable at a price of 9.00 euros and subject to the Company entering into a licensing agreement or obtaining marketing authorization for at least two indications and with at least one of its molecules, including 760,894 BSAs subscribed by Meeteam, 19,327 warrants in remuneration of a contributor and 15,000 warrants to directors, 125,000 stock options to Company employees. Finally, in September 2024, 12,539 free shares (AGAP B'), issued one year earlier, were definitively allocated. At its meeting on 3 January 2025, the Board of Directors noted that the stock options and warrants listed below had lapsed, as the exercisability of these securities was conditional on the Company obtaining marketing authorisation for masitinib before 31 December 2024. Securities Name Date granted by the Board of Directors Beneficiary Number of securities BSA BSA 2021-A 28/09/2021 AMY SAS 1.000.000 BSA BSA QN2 28/09/2021 Quercegen 800.000 BSA BSA QN3 28/09/2021 Quercegen 20.000 SO SO2019-A 20/05/2019 Guy, Laurent 274.000 SO SO2019-B 10/07/2019 Guy, Laurent 59.000 On 3 January 2025, the Board of Directors also noted, after reviewing the terms and conditions of the B preference shares (and in particular the operational criteria and the financial performance criteria that must be met for the B shares to be converted into ordinary shares), that out of a total of 45,134 B shares: 37,427 B shares may not be converted into ordinary shares and will therefore be bought back by the Company at their nominal value with a view to their cancellation; and 7,707 B shares may be converted into 419,982 ordinary shares with effect from 1st January 2025. On 17 January 2025, the President of the Paris Business Court opened conciliation proceedings in favour of AB Science for a period of four months, and appointed SELARL AJ UP, represented by Maître Paul-Henri Audras, as conciliator. The task of the conciliator is to negotiate with AB Science's banking partners and to facilitate the release of the CIR2023. The bank debts currently being repaid are PGEs and an innovation loan totalling €3.8 million (at 31 December 2024). AB Science's objective is to concentrate resources on its R&D programme. Finally, the CIR 2023 (also the subject of the conciliation procedure) is for an amount of €3.45 million. In April 2025, 15,000 free shares (AGAP B') were issued. These free shares will be definitively allocated in April 2026. On 28 April 2025, the PACTTM programme was extended identically for a period of 12 months. About AB ScienceFounded in 2001, AB Science is a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), a class of targeted proteins whose action are key in signaling pathways within cells. Our programs target only diseases with high unmet medical needs, often lethal with short term survival or rare or refractory to previous line of treatment. AB Science has developed a proprietary portfolio of molecules and the Company’s lead compound, masitinib, has already been registered for veterinary medicine and is developed in human medicine in oncology, neurological diseases, inflammatory diseases and viral diseases. The company is headquartered in Paris, France, and listed on Euronext Paris (ticker: AB). Further information is available on AB Science’s website: www.ab-science.com. Forward-looking Statements - AB ScienceThis press release contains forward-looking statements. These statements are not historical facts. These statements include projections and estimates as well as the assumptions on which they are based, statements based on projects, objectives, intentions and expectations regarding financial results, events, operations, future services, product development and their potential or future performance. These forward-looking statements can often be identified by the words "expect", "anticipate", "believe", "intend", "estimate" or "plan" as well as other similar terms. While AB Science believes these forward-looking statements are reasonable, investors are cautioned that these forward-looking statements are subject to numerous risks and uncertainties that are difficult to predict and generally beyond the control of AB Science and which may imply that results and actual events significantly differ from those expressed, induced or anticipated in the forward-looking information and statements. These risks and uncertainties include the uncertainties related to product development of the Company which may not be successful or to the marketing authorizations granted by competent authorities or, more generally, any factors that may affect marketing capacity of the products developed by AB Science, as well as those developed or identified in the public documents published by AB Science. AB Science disclaims any obligation or undertaking to update the forward-looking information and statements, subject to the applicable regulations, in particular articles 223-1 et seq. of the AMF General Regulations. For additional information, please contact: AB ScienceFinancial Communication & Media Relations investors@ab-science.com Attachment AB SCIENCE Resultats 2024 VEng VF The post AB Science reports its revenues for the year 2024 and provides an update on its activities appeared first on ForexTV.

Banco Comercial Português, S.A. informs about Bank Millennium (Poland) results in Q1 2025 Attachment 2025 05 12 Resultados Polónia_EN The post Banco Comercial Português, S.A. informs about Bank Millennium (Poland) results in Q1 2025 appeared first on ForexTV.

NEW DELHI, May 12, 2025 (GLOBE NEWSWIRE) -- Colab Platforms is created by visionaries passionate about transforming the sports industry. By merging technology, management, and content, they redefine how sports are played, managed, and experienced at every level. Colab Cloud Platforms Ltd., a BSE-listed Indian company (BSE: 542866), is a leading technology solutions provider and is excited to announce its strategic expansion into the Sports Management and Sports Technology sectors. According to Brainy Insights, a global market research firm, the global sports market was valued at $480.12 billion in 2023 and is projected to grow at a CAGR of 5.6%, reaching $506.93 billion in 2024. India’s sports and fitness sector is expected to reach a massive ₹50,000 crore (approximately USD 6 billion) market size, driven by rising health awareness, digital platform adoption, and increased sports participation. Colab Cloud aims to capitalize on this growing opportunity by delivering tech-enabled solutions tailored to the needs of modern sports consumers and professionals. Sports Marketplace – Learn, Play & Shop. The Sports Ecosystem Marketplace is a one-stop platform where athletes and sports lovers can Learn, Play, and Shop all in one place. Book top coaches and academies to level up your game, play by finding and booking turfs, stadiums, and other sports infrastructure nearby, and shop for high-quality gear, accessories, and nutrition from trusted brands. It’s your all-in-one hub to train, compete, and gear up with ease. Colab Cloud will leverage its expertise across key segments of the sports industry. This expansion includes advanced solutions for managing sports Intellectual Properties (IPs), fan engagement platforms, and immersive Virtual Reality (VR) and Augmented Reality (AR) experiences. By integrating cutting-edge technologies into the sports and gaming sectors, Colab Cloud aims to drive innovation and transformation. This approach will streamline operations, enhance fan engagement, and unlock new market opportunities. The company intends to deliver tailored solutions in sports management, technology, and marketing, aiming to become a key player in the evolving sports ecosystem. Key trends in the Indian sports market include rising direct engagement between sports entities and fans, growing interest in diverse sports, and increasing demand for VR and AR experiences. Sports-themed gaming, digital fan communities, and immersive engagement platforms are also accelerating. “The convergence of technology and digital interaction is ushering in a new era of sports and gaming experiences,” said a company spokesperson. As part of this strategy, Colab Cloud has secured a franchise agreement with Arvus Sports Private Limited, the owner of the Big Cricket League (BCL), a T20 cricket league. Colab Cloud will own and manage the Northern Challengers, a professional men's cricket team under this agreement. The company also announced a strategic investment of up to INR 100 million to build a dedicated e-commerce marketplace for sports and fitness products. This initiative supports Colab Cloud’s vision of using technology to enhance user experiences and drive growth. The platform will offer a wide range of fitness gear, apparel, and accessories for athletes, fitness professionals, and health-conscious consumers. With India becoming a global fitness and wellness leader, this marketplace will provide seamless access to quality products. Colab Cloud Sports Technology includes VR/AR, AI-based personalization, and data analytics to enhance performance and engagement. The company’s Athlete Management solution equips players with tools to manage and grow their careers, secure sponsorships, showcase achievements, and access strategic opportunities—all powered by marketing insights and data. Its Sports Content & Media platform streamlines league-wide operations, tracking player and team activity from daily operations to full-season planning. Colab Cloud also offers Sponsorship & Marketing Solutions that maximize brand exposure through data-driven campaigns, enhancing visibility for athletes, teams, and events. The company is built by professionals deeply rooted in the sports industry. Their hands-on experience fosters innovative thinking and practical solutions. Colab Cloud brings a comprehensive tech approach that supports the entire sports community, pushing boundaries beyond conventional strategies. About Colab Cloud Platforms Ltd.:Colab Cloud Platforms Ltd. is a top 2000 company listed on the Bombay Stock Exchange. The company delivers innovative technology solutions across multiple industries, with a focus on enhancing user experiences and driving scalable growth. With India’s rise as a global tech hub, Colab Cloud leverages its skilled talent pool to provide customized, future-ready solutions that meet dynamic industry needs. For more information about Colab Cloud Platforms Ltd. and its services, please visit www.colabplatforms.com or follow the company on social media. Media Contact:Organization: Synergy Global Enterprise LLCName: Gopi DivechaAddress: 111 North Bridge Road #21–01, Singapore 179098Website: https://pixelproduction.com/Email: gopi@pixelproduction.com Disclaimer: This media platform provides the content of this article on an "as-is" basis, without any warranties or representations of any kind, express or implied. We do not assume any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information presented herein. Any concerns, complaints, or copyright issues related to this article should be directed to the content provider mentioned above. A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/05638ba9-13d5-4993-9af3-44acd1ce88a7 The post Cloud transforming the sports industry & Sports Ecosystem Marketplace Learn, Play & Shop appeared first on ForexTV.

NEW YORK, May 11, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Everus Construction Group, Inc. (“Everus” or “the Company”) (NYSE: ECG) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Everus common stock between October 31, 2024 and February 11, 2025, both dates inclusive (the “Class Period”), including investors who held MDU Resources Group, Inc. (“MDU Resources”) common stock as of October 21, 2024 and acquired Everus common stock issued in connection with the spinoff of Everus Construction (defined below) on or about October 31, 2024 (the “Spinoff”). Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/ECG. Case Details The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, the Complaint alleges that Defendants failed to disclose to investors that: (1) the Company’s backlog conversion cycle had become elongated due to larger, more complex projects; (2) as a result, the Company’s revenue recognition would be delayed; and (3) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. What's Next? A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: bgandg.com/ECG. or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660. If you suffered a loss in Everus you have until June 3, 2025, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff. There is No Cost to You We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful. Why Bronstein, Gewirtz & Grossman Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide. Follow us for updates on LinkedIn, X, Facebook, or Instagram. Attorney advertising. Prior results do not guarantee similar outcomes. Contact Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Nathan Miller 332-239-2660 | info@bgandg.com The post ECG INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Everus Construction Group, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit appeared first on ForexTV.

NEW YORK, May 11, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Canopy Growth Corporation (“Canopy” or “the Company”) (NASDAQ: CGC) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Canopy securities between May 30, 2024 and February 6, 2025, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/CGC. Case Details The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding Canopy's business, operations, and prospects. Specifically, the Complaint alleges that Defendants made false and/or misleading statements and/or failed to disclose that: (1) Canopy had incurred significant costs producing Claybourne pre-rolled joints in connection with the Claybourne product launch in Canada; (2) the foregoing costs, in addition to certain indirect costs that Canopy incurred in connection with its Storz & Bickel vaporizer devices, were likely to have a significant negative impact on the Company's gross margins and overall financial results; (3) accordingly, Defendants had overstated the efficacy of Canopy's cost reduction measures and the health of its gross margins while downplaying issues with the same; and (iv) as a result, Defendants' public statements were materially false and misleading at all relevant times. What's Next? A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: bgandg.com/CGC. or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660. If you suffered a loss in Canopy you have until June 3, 2025, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff. There is No Cost to You We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful. Why Bronstein, Gewirtz & Grossman Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide. Follow us for updates on LinkedIn, X, Facebook, or Instagram. Attorney advertising. Prior results do not guarantee similar outcomes. Contact Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Nathan Miller 332-239-2660 | info@bgandg.com The post CGC INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Canopy Growth Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit appeared first on ForexTV.

Built into Optimove’s Positionless Marketing Platform, Engage is the engine behind Creative Power enabling real-time content creation, management, and optimization New York, May 11, 2025 (GLOBE NEWSWIRE) -- Optimove, the leader in Positionless Marketing, today announced the launch of Optimove Engage, an AI-powered solution that empowers marketers to scale the creation, management, and optimization of personalized content across every channel. In the GenAI era, generating personalized content is easier than ever. But with infinite permutations now possible, a new challenge has emerged: how to manage, test, and optimize it without spiraling into content chaos that’s overwhelming many marketing teams today. Optimove Engage provides marketing teams with: GenAI-powered, brand-compliant content creation and management across all channels AI-led message analysis that identifies each customer’s content palette and continuously optimizes delivery A marketer-friendly UI to facilitate true messaging symmetry across outbound and inbound channels “GenAI has empowered anyone to create content instantly. While that’s accelerated creativity, it’s also unleashed a runaway train of content chaos,” said Shai Frank, SVP Product & GM Americas at Optimove. “Engage is the engine behind Creative Power in our Positionless Marketing platform, enabling real-time content creation, management, and optimization at scale. It’s built for marketers to meet today’s customer expectations, where speed and relevance are everything. With Engage, marketers can truly be positionless, executing AI-assisted campaigns with control that drives engagement and loyalty.” Optimove Engage adds a powerful content optimization layer to the Optimove Positionless Marketing Platform. It joins: Optimove Orchestrate – the industry standard-setting orchestration and decisioning engine, providing a Single Marketing View of all campaigns across channels and vendors Opti-X – the personalization engine that delivers tailored digital experiences at scale Adact.me – the AI-orchestrated gamification solution enhancing engagement and retention OptiGenie – the foundational, generative, and agentic AI framework behind Optimove Together, these solutions empower marketers to deliver real-time, individualized journeys with full visibility and control. All within a single, unified platform. The Positionless Marketing Platform Powers the Entire Marketing Workflow Optimove’s Positionless Marketing Platform is built on three foundational powers:  Data Power – Allowing marketers to discover customer insights instantly for precise targeting and hyper-personalization. Creative Power – Empowering marketers to generate channel-ready assets like copy and visuals instantly. Optimization Power – Enabling complete marketing teams to run self-optimizing campaigns through automated journeys and testing.  With Optimove’s Positionless Marketing Platform, marketers gain full control over the entire marketing lifecycle, executing any task instantly and independently. From orchestration to optimization, it lets marketers break free from the limitations of fixed roles and gain the power to execute any marketing task instantly and independently to do anything and be everything.  About Optimove  Optimove, the leader in Positionless Marketing, frees marketing teams from the limitations of fixed roles, giving every marketer the power to execute any marketing task instantly and independently. Positionless Marketing has been proven to improve campaign efficiency by 88%, allowing marketing teams to create more personalized engagement with existing customers.   Optimove is recognized as the Visionary Leader in Gartner’s Magic Quadrant for Multichannel Marketing Hubs. Being a visionary leader is a hallmark of Optimove. It was the first CRM Marketing Platform to natively embed AI with the ability to predict customer migrations between lifecycle stages in 2012.   Today, its comprehensive AI-powered suite is at the leading edge of empowering marketers to optimize workflows from Insight to Creation and through Orchestration.  Optimove provides industry-specific and use-case solutions for leading consumer brands globally.  For more information, go to Optimove.com     CONTACT: Rob Wyse Optimove +2129201470 Rob_W@optimove.com The post Optimove Launches Engage to End “Content Chaos” in the GenAI Age appeared first on ForexTV.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In The Bancorp To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in The Bancorp between January 25, 2024 and March 4, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, May 11, 2025 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against The Bancorp, Inc. (“TBBK” or the “Company”) (NASDAQ: TBBK) and reminds investors of the May 16, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com. As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) that Bancorp had underrepresented the significant risk of default or loss on its REBL loan portfolio; (2) that the Company’s current expected credit loss methodology was insufficient to account for the provision and/or allowance of credit losses; (3) that, as a result of the foregoing, the Company was reasonably likely to increase its provision for credit losses; (4) that there were material weakness in its internal control over financial reporting; (5) that its financial statements had not been approved by its independent auditor; (6) that, as a result of the foregoing, the Company’s financial statements could not be relied upon; and (7) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. On March 21, 2024, at approximately 9:45 a.m. EST, Culper Research issued a report, alleging that the Company had underrepresented significant risks of default and/or loss on certain real estate bridge loans (“REBLs”). The report alleged the Company’s loan book is “rife with unsophisticated syndicated borrowers” who were “coaxed by promises of generational wealth through passive income” with “get rich quick” promises. The report alleged that the Company’s REBL loan portfolio is filled with apartments which are “quite literally, crumbling,” with high vacancies and multiple condemnations. The report stated the Company “blindly reassures investors that its book contains ‘no substantial risk of default or loss,’” but, in reality, the Company’s “REBL portfolio faces meaningful risks and will result in meaningful losses.” The report concluded that the Company’s reserve of only “$4.7 million in REBL loan allowances, representing a mere 0.24% of the total REBL book” is “short by an order of magnitude or more.” On this news, the Company’s share price fell $3.63, or 10.15%, to close at $32.12 per share on March 21, 2024, on unusually heavy trading volume. Then, on October 24, 2024, after the market closed, the Company announced its third quarter 2024 financial results in a press release for the period ended September 30, 2024, reporting $51.5 million in net income. The Company attributed the results in part, to “a new CECL [current expected credit losses methodology] factor” to the Company’s analysis of REBL loans classified as either special mention or substandard “which increased the provision for credit losses and resulted in an after-tax reduction in net income of $1.5 million.” The Company further explained its results also reflected “prior period interest income reversals on real estate bridge loans transferred to nonaccrual or modified” which “resulted in an after-tax reduction in net income of $1.2 million.” On this news, the Company’s share price fell $7.95, or 14.47%, to close at $47.01 per share on October 25, 2024, on unusually heavy trading volume. Finally, on March 4, 2025, after the market closed, Bancorp disclosed that its “financial statements for the fiscal years ended December 31, 2022 through 2024 as shown in the Annual Report should no longer be relied upon.” The Company explained that its auditors for those years “did not provide approval to include [the] audit opinion . . . or [the] consent to the incorporation by reference of their audit report in certain registration statements.” The Company further revealed it is “working expeditiously to perform and complete additional closing procedures related to accounting for consumer fintech loans in the allowance for credit losses” in order to file an amended annual report. The Company also revealed it “is evaluating the impact of this non-reliance on its conclusions regarding disclosure controls and procedures and internal control over financial reporting.” As a result of the foregoing, the Company stated it would be unable to file timely its fiscal year 2024 annual report. On this news, the Company’s share price fell $2.34, or 4.38%, to close at $51.25 per share on March 5, 2025, on unusually heavy trading volume. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.   Faruqi & Faruqi, LLP also encourages anyone with information regarding The Bancorp’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others. To learn more about the Bancorp class action, go to www.faruqilaw.com/TBBK or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Follow us for updates on LinkedIn, on X, or on Facebook. Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner. The post Faruqi & Faruqi Reminds The Bancorp Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 16, 2025 – TBBK appeared first on ForexTV.

LOS ANGELES, May 10, 2025 (GLOBE NEWSWIRE) -- If you're dealing with stubborn weight, low energy, or sluggish metabolism, Mitolyn could be the breakthrough you've been looking for. Promoted as a next-generation mitochondrial support supplement, Mitolyn is gaining attention across health communities and social platforms like Reddit, sparking conversations about its actual results compared to the growing buzz. In this detailed Mitolyn review, we’ll take a close look at ingredients, benefits, potential side effects, and what real users are saying. Whether you’re searching for Mitolyn weight loss reviews, wondering if the product is legitimate, or curious about feedback and complaints found on platforms like Consumer Reports and Amazon, this guide covers it all with clarity and scientific backing. Made with six unique plant-based ingredients, Mitolyn is designed to enhance mitochondrial function, naturally boost metabolism, and support fat burning. It is non-GMO, free from stimulants, and supported by clinical research, setting it apart in the crowded supplement market. Curious to find out what Mitolyn is really all about? Let’s dive in. [Click Here to the Official Website ] What Is Mitolyn? Mitolyn is a dietary supplement formulated to boost metabolism, elevate energy levels, and support fat loss by targeting the body’s cellular powerhouse, the mitochondria. Developed with a proprietary blend of six plant-based, science-supported ingredients, Mitolyn works to naturally enhance mitochondrial function, helping your body burn more calories and convert fat into usable energy. Unlike conventional weight loss supplements that depend on caffeine or strong stimulants, Mitolyn is non-GMO, free of stimulants, and non-habit-forming. Its formula features ingredients such as Maqui Berry, Rhodiola, Amla, and Haematococcus. These have been highlighted in peer-reviewed studies for their ability to support mitochondrial health, reduce oxidative stress, and promote healthy fat metabolism. Mitolyn is manufactured in the USA using a combination of domestic and globally sourced ingredients. It also comes with a 90-day money-back guarantee. The supplement has gained significant attention in 2025 for its natural fat-burning approach and strong link to cutting-edge mitochondrial research, as reflected in numerous Mitolyn reviews and customer testimonials. Whether you're exploring Mitolyn weight loss reviews, searching for real user results, or wondering if Mitolyn is legitimate or a scam, knowing what it is and how it works is the essential first step toward making an informed choice. >> Get to Know Mitolyn And See the Benefits Mitolyn Ingredients: A Comprehensive Analysis Backed by Science When selecting a weight loss or metabolism-boosting supplement, understanding the ingredients is just as important as knowing how the product works. Mitolyn has rapidly gained recognition in 2025 for its mitochondria-focused approach to fat burning, with much of the attention centered around its distinctive ingredient formula. Unlike many conventional weight loss products, Mitolyn uses natural, plant-based compounds that have been scientifically proven to support mitochondrial function, increase energy levels, and aid in fat metabolism. It achieves this without relying on stimulants or synthetic additives. In this detailed breakdown, we will examine each of the six key ingredients found in Mitolyn, highlight their science-backed benefits, and explain why this supplement is becoming increasingly popular on health platforms such as Reddit, Amazon, and Consumer Reports. Mitolyn’s 6 Core Ingredients (with Scientific Support) Maqui Berry What it is: A dark purple berry native to Chile, known for its high concentration of anthocyanins, a group of powerful antioxidants. Benefits: Encourages the formation of new mitochondria (mitochondrial biogenesis) Supports cardiovascular health and healthy cholesterol levels Helps reduce oxidative stress Scientific Insight: Research indicates that anthocyanins can stimulate mitochondrial thermogenesis and help convert white fat into beige fat, promoting fat burning. Rhodiola Rosea What it is: An adaptogenic herb traditionally used to fight fatigue and enhance physical endurance. Benefits: Boosts cellular energy production Helps manage stress-related weight gain Enhances focus and mental performance Scientific Insight: The polyphenols in Rhodiola, especially salidroside, have been found to increase ATP production by activating mitochondrial function. Haematococcus Pluvialis (Astaxanthin) What it is: A type of freshwater algae that produces astaxanthin, one of the most potent natural antioxidants. Benefits: Enhances mitochondrial efficiency in muscle cells Promotes joint and immune system health Reduces inflammation Scientific Insight: Astaxanthin has been shown to activate the AMPK pathway, which plays a role in generating new mitochondria and boosting metabolism. Amla (Indian Gooseberry) What it is: A nutrient-dense fruit packed with vitamin C, polyphenols, and flavonoids. Benefits: Increases mitochondrial respiration capacity Supports digestion and eye health Exhibits natural anti-obesity effects Scientific Insight: Studies show that Amla strengthens mitochondrial antioxidant defenses and enhances energy output, particularly in skeletal muscle cells. Theobroma Cacao (Cocoa Extract) What it is: The plant from which chocolate is derived, is rich in the flavonoid epicatechin. Benefits: Improves circulation and supports heart health Known for its mood-boosting and aphrodisiac properties Assists in mitochondrial repair and regeneration Scientific Insight: Epicatechin has been found to improve the structure and performance of mitochondria, especially in individuals with metabolic or cardiovascular conditions. Schisandra Chinensis What it is: A bright red berry used in traditional Chinese medicine, known for its high lignan and antioxidant content. Benefits: Enhances fat oxidation and supports liver detoxification Aids in maintaining youthful skin Increases the body’s resilience to stress Scientific Insight: Schisandrin C has been shown to trigger both mitochondrial biogenesis and autophagy in muscle cells, leading to better endurance and metabolic health. >>Is the Mitolyn backed by science? Review our analysis or check out the official website for product info How Does Mitolyn Work? A Scientific Look at Its Fat-Burning Power If you’re dealing with low energy, persistent belly fat, or a slow metabolism, you’re not alone. These common issues are exactly what Mitolyn is designed to target. But how does it actually work? At its foundation, Mitolyn is a supplement formulated to support mitochondrial function. Unlike typical weight loss pills that depend on caffeine or temporary water loss, Mitolyn focuses on improving the underlying cause of a sluggish metabolism: poorly functioning mitochondria. Here’s a closer look at how Mitolyn delivers its fat-burning and energy-boosting effects, and why many users report positive changes in energy, fat loss, and mood. Mitochondria: Your Body’s Energy and Fat-Burning Core Mitochondria are tiny structures located within almost every cell in your body. They convert food into ATP (energy), which fuels everything from brain activity to fat breakdown. Scientific research, including findings from institutions like Harvard and the NIH, has shown a clear connection: A lower number of mitochondria can lead to fatigue, weight gain, and a slower metabolism A higher level of mitochondrial activity promotes faster calorie burning, more energy, and improved body composition This is where Mitolyn offers a unique advantage. What Sets Mitolyn Apart Mitolyn’s carefully selected ingredients work together to: Promote Mitochondrial Biogenesis: Compounds such as Rhodiola, Astaxanthin (from Haematococcus), and Maqui Berry help activate the creation of new mitochondria, which is known as biogenesis. Improve Existing Mitochondria Function: Ingredients like Amla, Epicatechin (from Cocoa), and Schisandra help maximize the energy output of the mitochondria you already have. This helps your body burn fat and glucose more efficiently without the need for stimulants. Lower Oxidative Stress: Several of Mitolyn’s components act as powerful antioxidants. These protect mitochondria from cellular damage and support their long-term function, particularly during fat metabolism. Why This Supports Fat Loss and Energy When mitochondria function at a higher level, your body is able to: Burn more fat even while at rest Convert food into usable energy instead of storing it Improve how it processes calories, reducing the chances of fat storage Stabilize energy levels and reduce food cravings This helps explain why so many users report improved stamina, steady fat loss, and better mood without experiencing the crash or jittery effects associated with stimulant-based fat burners. In addition, Mitolyn includes adaptogens like Rhodiola and Schisandra. These ingredients help the body manage stress, balance cortisol levels, and enhance mental focus, providing cognitive benefits alongside physical ones. In summary, Mitolyn works by fueling the very systems that power your metabolism. If you’re looking for a long-term, science-based approach to fat-burning and energy support, Mitolyn could be a supplement worth exploring. >>Curious about Mitolyn's fat-burning claims? Check out the full review and visit the official website for more info Benefits of Mitolyn Mitolyn is a mitochondria-focused supplement that delivers more than just fat-burning effects. Its plant-based formula works deep within your cells to support overall health and wellness. Backed by scientific studies and verified Mitolyn reviews from 2025, here are the key benefits: 1. Naturally Boosts Metabolism Mitolyn helps your body produce more mitochondria and improves their efficiency. As a result, your metabolism speeds up and burns more calories even during rest, making it easier to lose persistent fat. 2. Enhances Energy and Reduces Fatigue By supporting the body’s production of ATP, Mitolyn delivers steady, clean energy without relying on stimulants. Many users say they feel more energized, focused, and productive throughout the day without experiencing crashes. 3. Aids in Weight Loss User testimonials highlight impressive weight loss results, including reports of shedding 20, 30, or even 40 pounds. By encouraging fat oxidation and supporting metabolic balance, Mitolyn promotes gradual and long-lasting weight reduction, particularly around the midsection. 4. Improves Mental Clarity and Mood Key adaptogens like Rhodiola and Schisandra help manage cortisol levels, reduce stress, and support emotional balance. Users often report better focus, improved concentration, and a calmer mental state. 5. Supports Heart, Liver, and Skin Health With antioxidant-rich ingredients such as Astaxanthin, Maqui Berry, and Amla, Mitolyn works to protect cells from oxidative stress. This supports cardiovascular wellness, and healthy liver function, and helps maintain skin firmness and elasticity. 6. Safe, Natural, and Non-Habit Forming Made without stimulants Contains no GMOs Free from synthetic additives Manufactured in the USA using high-quality global ingredients Mitolyn is formulated for long-term use with a low risk of side effects. According to Mitolyn reviews across Reddit and other platforms, users consistently report feeling healthier, more energetic, and more confident in their bodies. How to Use Mitolyn: Dosing and Directions for Optimal Results If you're ready to experience the fat-burning and energy-boosting benefits of Mitolyn, it's essential to take it properly. Following the correct dosage and usage guidelines will help you maximize its effects while minimizing any potential side effects. Here’s a simple guide on how to use Mitolyn safely and effectively. Mitolyn Dosage: How Much Should You Take? Recommended Dose: Take 2 capsules daily with a full glass of water. When to Take: For the best results, take Mitolyn in the morning, ideally with breakfast, to help support your energy and metabolism throughout the day. Some users find that taking it with a light meal can help reduce any mild digestive discomfort during the initial use. Consistency Is Important Mitolyn’s benefits develop over time. To optimize mitochondrial health, fat metabolism, and sustained energy, it's important to: Take it daily without skipping doses. Use it for at least 60 to 90 days to allow the natural ingredients to fully take effect. Drink plenty of water and maintain a balanced diet for better absorption. Pro Tips for Best Results Pair with the free bonus detox guide: If you've purchased 3 or 6 bottles, use the “1-Day Kickstart Detox” to help flush toxins and prepare your body for Mitolyn. Manage stress and get enough sleep: Adaptogenic ingredients like Rhodiola and Schisandra work best when you get sufficient rest and reduce stress levels. Incorporate light exercise: Even activities like walking or stretching can enhance the mitochondrial-boosting effects of Mitolyn over time. Important Usage Warnings Do not exceed the recommended dosage (2 capsules per day). Consult a healthcare provider if you are pregnant, breastfeeding, have a medical condition or are taking prescription medications. Not intended for individuals under the age of 18. Taking Mitolyn is easy, just two capsules a day consistently can help you unlock more energy, improve your metabolism, and long-term fat-burning support. Many users notice increased stamina and improved mood within the first few weeks, with the full benefits becoming more noticeable after 2 to 3 months of regular use. Mitolyn Side Effects: Is It Safe? If you're thinking about adding Mitolyn to your wellness or weight loss routine, it's completely valid to prioritize safety. With increasing interest in Mitolyn reviews and user feedback, it's important to look at both the benefits and the potential side effects of this supplement. Clinically-Inspired and Naturally Formulated Mitolyn contains a proprietary blend of six plant-based ingredients, including Maqui Berry, Rhodiola, Amla, Astaxanthin, Schisandra, and Theobroma Cacao. The formula is free from GMOs and synthetic stimulants, and its ingredients are supported by scientific studies focused on mitochondrial and metabolic health. User-Reported Safety and Experience Based on 2025 Mitolyn reviews from platforms such as Reddit, Amazon, and Consumer Reports, the majority of users have not experienced significant side effects. The most commonly reported results include: Elevated energy levels Better digestion Enhanced mood No crashes or jitteriness often seen with stimulant-based fat burners These outcomes support Mitolyn’s reputation for being non-addictive and suitable for regular, long-term use. Mild Side Effects That May Occur Although most users tolerate Mitolyn well, a small number may notice mild effects during the initial adjustment period. These may include: Digestive changes like bloating or gas Slight headaches or fatigue as part of the body’s detox response Increased urination as metabolism becomes more active Such effects tend to be brief and typically resolve within a few days. Who Should Use Caution? While Mitolyn is safe for most healthy adults, certain individuals should speak with a healthcare provider before using it, especially if they: Are pregnant or nursing Have liver or kidney conditions Take prescription medications for thyroid, blood pressure, or mental health As with any dietary supplement, it is best to read the label carefully and consult your physician if you have underlying medical concerns or are currently on medication. >>Is Mitolyn safe and effective? Visit the official website for verified product info Mitolyn Pros and Cons Before committing to any supplement, it's important to consider both the benefits and potential drawbacks. Based on user experiences, expert evaluations, and clinical evidence, here is a detailed list of Mitolyn's pros and cons to help you make an informed decision. Pros Targets the root cause of slow metabolism Made from natural, plant-based ingredients Increases energy without causing jitters Supports long-term weight loss Enhances mood, focus, and stress resilience Manufactured in the USA with research backing its formula Comes with a 100% risk-free guarantee Cons Results may take time to become noticeable Available only through online retailers Some mild initial side effects The pros of Mitolyn strongly outweigh the cons for those seeking a natural and sustainable solution to slow metabolism, low energy, and weight gain. While it may take time and require an investment, the growing number of positive reviews and the scientific foundation behind the product make it a standout choice in the supplement market. Mitolyn Customer Reviews And Complaints Mitolyn is gaining significant attention in the metabolic health supplement market, and many users are curious about whether it lives up to the hype. With its focus on mitochondrial support and a blend of plant-based ingredients, Mitolyn is designed to promote fat burning, enhance energy levels, and support overall vitality without relying on stimulants. But how well does it actually perform in real-world use? Boasting an impressive average rating of 4.92 out of 5, the majority of thenMitolyn reviews reflect high levels of satisfaction among users. However, a few customer complaints and user observations are worth considering. Here is a clear and honest breakdown of feedback from actual customers based on various lengths of use. 30-Day Mitolyn Reviews "Within a month of using Mitolyn, my energy levels have noticeably improved. No more afternoon crashes, and I’ve already lost 5 pounds without changing much in my routine." - Jessica M., 38, Austin, TX 90-Day Mitolyn Reviews "After three months, I’ve dropped 15 pounds and feel like my metabolism is finally working again. I have more stamina and feel healthier overall." - Brian S., 50, Denver, CO 180-Day Mitolyn Reviews "Six months into using Mitolyn, and I’ve lost 30 pounds. I feel stronger, healthier, and more confident than I have in years. It’s been life-changing." - Karen D., 55, San Diego, CA >>Want to read more real Mitolyn reviews? Check out the genuine customer feedback on the official website Common Mitolyn Complaints Although most Mitolyn feedback is highly positive, a few user reviews and concerns highlight some areas to consider: Slow Progress: Some users report that noticeable weight loss requires consistent use over a period of 2 to 3 months. Cost Concerns: Priced between $49 and $79 per bottle, a few users consider it a significant investment, though many feel the benefits make it worthwhile. Limited Availability: Mitolyn is only available through the official website, and not sold in physical stores or on Amazon, which can be inconvenient for some. Mild Reactions: A small number of users mention experiencing temporary bloating or digestive issues during the initial phase. If you are looking for a stimulant-free supplement with natural ingredients and science-backed mitochondrial support, Mitolyn presents a strong option. Real testimonials from platforms like Reddit and Consumer Reports reflect improvements in energy, weight management, and overall health. While it may not produce instant results, Mitolyn’s long-term advantages make it a leading wellness choice in 2025 for those committed to improving their health. Mitolyn Pricing Options Mitolyn offers several bundle options to suit your goals and budget. As of now, the current pricing is: Basic Pack – 1 Bottle (30-day supply): $79 Bundle Pack – 3 Bottles (90-day supply): $177 Most Popular – 6 Bottles (180-day supply): $294 The lowest cost per bottle is just $49 when you purchase the 6-bottle bundle. Where to Buy Mitolyn Mitolyn is exclusively available through its official website. You won't find it on Amazon, Walmart, eBay, or any other third-party online retailers. This ensures that you receive the genuine product and helps prevent counterfeit or expired versions from circulating. Purchasing from the official website also guarantees access to customer support, bonuses, and refund options. >>Visit the official website to avoid third-party duplicates and counterfeit products Free Bonuses With 3 or 6 Bottles When you buy 3 or 6 bottles, you'll receive two exclusive eBooks: 1-Day Kickstart Detox: 20 simple detox tea recipes to help flush out toxins and kickstart your results. Renew You: Mindset tools designed to support stress relief, confidence, and mood. Refund Policy: 90-Day Money-Back Guarantee Mitolyn offers a 100% risk-free, 90-day money-back guarantee. If you're not fully satisfied with your results, whether due to side effects, slow progress, or any other reason, you can request a full refund. Simply contact customer support within 90 days of your purchase and return the bottles (even if they are empty) to receive your refund. Customer Support Contact Information If you require assistance with your order, tracking, refunds, or product details, Mitolyn’s customer support team is responsive and based in the U.S. Email Support: contact@mitolyn.com Return Address: 75 3rd Ave, New York, NY 10003, USA Shipping: Fast and secure; free shipping on 6-bottle orders within the U.S. To ensure you receive authentic products, bonus eligibility, and refund protection, the safest place to purchase Mitolyn is through the official website. With competitive bundle pricing, a generous return policy, and a science-backed formula, Mitolyn is a solid choice for those looking to take control of their metabolism and energy. Mitolyn: Scam or Legit? The Truth Behind the Hype With so many supplements available today, it's natural to question whether a trending product like Mitolyn is truly legitimate. You may have come across bold claims about rapid fat loss, increased energy, and enhanced health. But is Mitolyn a legitimate product, or just another overhyped scam? Let’s dive into the facts, based on scientific evidence, manufacturing standards, customer feedback, and refund policies. Why Mitolyn Is Legit Backed by Mitochondrial Science Mitolyn is not based on generic promises. It targets mitochondrial function, the core of your metabolism, using a proprietary blend of six scientifically supported ingredients, including: Maqui Berry (anthocyanins) Rhodiola Rosea (adaptogen) Haematococcus (Astaxanthin) Amla, Schisandra, and Theobroma Cacao These ingredients are backed by peer-reviewed studies that link them to enhanced fat metabolism, increased energy production, and improved cellular health. Manufactured in the USA in a GMP and FDA-Registered Facility Mitolyn is produced in a Good Manufacturing Practices (GMP) and FDA-registered facility, which ensures high standards of quality, purity, and safety. It is: Non-GMO Stimulant-free Free from artificial additives Non-habit forming 90-Day Money-Back Guarantee Concerned about wasting your money? Mitolyn offers a 100% money-back guarantee for 90 days. If you don't see results, you can receive a full refund with no questions asked. This is a strong indication of trust, which is not typically offered by scam products. Real Mitolyn Reviews from Verified Users With a 4.95/5 star rating and over 95,000 verified reviews, Mitolyn has earned high praise for: Sustained energy Fat loss (10 to 40 lbs reported within 90 to 180 days) Reduced fatigue and improved digestion Still skeptical? Check Mitolyn reviews on Reddit, complaints forums, or Consumer Reports. Most feedback affirms that the product delivers results with consistent use. Mitolyn is 100% legit. It’s grounded in authentic science, produced in a trusted facility, and has been praised by thousands of satisfied users. While it may not be an overnight fix, it is a credible, safe, and effective supplement for those seeking long-term support for energy, metabolism, and fat-burning. Final Verdict: Is Mitolyn Worth the Investment? After carefully reviewing Mitolyn’s ingredients, benefits, user testimonials, and scientific support, the key question remains: Is Mitolyn truly worth it? Unlike many weight loss supplements that rely on caffeine, water retention, or crash dieting tactics, Mitolyn uses natural, stimulant-free ingredients that support energy and fat loss at a cellular level. The blend of Maqui Berry, Rhodiola, Schisandra, and other ingredients is backed by real scientific research and thousands of positive Mitolyn reviews. Mitolyn is not a scam; it is a legitimate, well-crafted supplement that delivers results for those who are dedicated to their health. Whether you’re dealing with low energy, weight issues, or metabolic challenges, this mitochondrial-supporting formula offers a safe, natural, and sustainable solution. If you’re serious about improving your energy and metabolism from the inside out, Mitolyn is certainly worth the investment. Email: contact@mitolyn.com Disclaimer: The information provided about Mitolyn has not been evaluated or approved by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary. As with any dietary supplement, it is essential to consult with your healthcare provider before beginning use, especially if you are managing a medical condition or taking prescription medications. This content is for informational and educational purposes only and should not be considered medical advice. Some of the links in this article may be affiliate links, meaning we could earn a small commission if you make a purchase. Always consult a licensed medical professional before adding Mitolyn or any mitochondrial or metabolic support supplement to your health routine. Photos accompanying this announcement are available at:https://www.globenewswire.com/NewsRoom/AttachmentNg/dd5c30ea-2ef6-4c4c-b314-62f6ed457e79https://www.globenewswire.com/NewsRoom/AttachmentNg/2d4cfdba-76da-4859-868d-a159c53e92b3https://www.globenewswire.com/NewsRoom/AttachmentNg/c645d5c4-0030-4aab-8343-21169db7d65ahttps://www.globenewswire.com/NewsRoom/AttachmentNg/ef9ce49f-f8a8-471c-8fb0-51785a30e753 The post Mitolyn Reviews 2025: Ingredients, Real User Results, Pros and Cons! Honest Review Inside! appeared first on ForexTV.

Bitcoin rockets to $102K, the Senate blocks a crypto bill over Trump ties, Ripple settles with the SEC, and Mashinsky gets 12 years. Read Full Story The post Bitcoin price rockets past $103K — Is it headed for new highs? appeared first on ForexTV.

Staten Island, NY, May 10, 2025 (GLOBE NEWSWIRE) -- Statement from Frank Siller, Chairman and CEO of the Tunnel to Towers Foundation: “The Tunnel to Towers Foundation fully supports President Trump’s Executive Order to establish the National Center for Warrior Independence on the West Los Angeles VA Campus. This bold and much-needed directive reflects our shared commitment to keeping America’s promise to its veterans—especially those experiencing homelessness. Tunnel to Towers has long believed that no veteran who served our country should be left to sleep on its streets. We have already provided housing and critical services to more than 10,000 homeless veterans nationwide, and we are proud to operate a facility on the West LA campus—directly serving veterans in the city with the highest concentration of homeless heroes in the country. This new Center will not only provide shelter, but a pathway to recovery, stability, and self-sufficiency through housing, treatment, and workforce reintegration. It is a transformational step toward turning what was once a symbol of neglect into a national model of restoration and respect. I look forward to sitting down with President Trump to discuss a comprehensive plan to build upon this momentum and further the Tunnel to Towers Foundation’s commitment to eradicating veteran homelessness once and for all. Together, we can restore dignity and deliver lasting change for the heroes who have sacrificed so much for this nation.” For more information about the Foundation’s programs supporting homeless veterans, visit T2T.org. About the Tunnel to Towers Foundation Born from the tragedy of 9/11, the Tunnel to Towers Foundation carries out its mission to "do good," by providing mortgage-free homes to Gold Star and fallen first responder families with young children and by building specially adapted smart homes for catastrophically injured veterans and first responders. Tunnel to Towers is also committed to eradicating veteran homelessness and helping America Never Forget September 11, 2001.  Visit T2T.org to learn more and follow Tunnel to Towers on Facebook, X, and Instagram.  CONTACT: Caroline Magyarits Tunnel to Towers Foundation 718-987-1931 caroline.magyarits@t2t.org The post Tunnel to Towers Foundation Applauds New Executive Order Supporting Homeless Veterans and Pledges Continued Partnership with President Trump appeared first on ForexTV.

A crypto analyst says Bitcoin is on its way to $160,000 or a “crazy number,” Alex Mashinsky gets 12 years jail, and more: Hodler’s Digest … Read Full Story The post Bitcoin eyes ‘crazy’ $160K, Mashinsky gets 12 years prison: Hodler’s Digest, May 4 – 10 appeared first on ForexTV.

Xi Jinping praises youth volunteers teaching in Xinjiang, highlighting their role in education, unity, and border development. Beijing, China, May 10, 2025 (GLOBE NEWSWIRE) -- Chinese people believe that letters are as valuable as gold. For thousands of years, letters, across mountains and oceans, have been delivering the writers' sentiments, and conveying friendship and expectations. Xi Jinping, general secretary of the Communist Party of China (CPC) Central Committee and Chinese president, has managed to find time to reply to some letters from different sectors of the society and different parts of the world despite his busy work schedule. Through his letters, Xi has corresponded with people from all walks of life on numerous occasions, part of a series of excellent stories of China in the new era. Therefore, the Global Times traced and contacted some of the recipients of Xi's letters to hear the inspiring stories behind the letters and their communications with the Chinese President. In this installment, representatives from a volunteer teaching team at a remote primary school in Northwest China's Xinjiang Uygur Autonomous Region, who recently received a reply letter from Xi, shared their stories of committing themselves to the western region, serving the border areas while promoting ethnic unity and progress. In the remote areas of vast western China, educational resources are not as developed as those in the eastern coastal regions. However, children in these regions have an equal right to education. To help bridge the gap, many young volunteers have set aside their studies or temporary jobs and left behind comfortable urban lives to travel to these areas, choosing to grow alongside the children and offer them opportunities for a broader and brighter future. Chinese President Xi Jinping has called on Chinese youth to dedicate themselves to the country's modernization drive by serving where the nation needs them most, the Xinhua News Agency reported on May 3. Xi, also general secretary of the Communist Party of China Central Committee and chairman of the Central Military Commission, made the remarks in a reply letter to a group of volunteer teachers working in a remote border school in Northwest China's Xinjiang Uygur Autonomous Region. On the occasion of China's Youth Day that falls on May 4, Xi extended festive greetings to young people across the country and expressed high expectations for their contributions in the letter. He commended the volunteers who are serving at a primary school in Karajol Township, Artux City, Kizilsu Kirgiz Autonomous Prefecture. The village school is located just 47 kilometers from China's border. "You have responded to the Party's call by teaching in the western border areas, where your efforts have not only promoted local education and ethnic unity but also contributed to prosperity and stability along the border," Xi said. According to Xinhua, the volunteers wrote to Xi to share their experiences and reaffirm their commitment to serving in China's border areas. Life-changing deeds Xieyite Primary School, a village-level school made up primarily of Kirgiz ethnic group students, is home to nearly 300 pupils, most of whom are children of border patrol officers. These officers have safeguarded the country's "western gate" for generations, according to a report by People's Daily. In August 2022, 23 volunteers from across the country participating in the "Go West" program arrived at Xieyite Primary School, embarking on their journey of teaching local students. Launched in 2003 by the Central Committee of the China Communist Youth League (CCYL), the "Go West" program is a collaborative endeavor that aims to send university graduates to volunteer in education, health, agriculture, and social management sectors in the country's western region for a period of one to three years. At Xieyite Primary School, after three years of volunteer teaching and with all the efforts of the volunteers, the school has seen a marked improvement in educational quality. The volunteer team, with an average age of just 24, was awarded the China Youth May Fourth Medal - the highest honor for Chinese youths aged 14 to 40 - granted by the CCYL and the All-China Youth Federation this year. In April, the school leadership and all 23 members of the volunteer team wrote a letter to President Xi, reporting on their experiences teaching in the border region and expressing their determination to take root in the west and serve the frontier areas, according to a report released by the local publicity department on its official WeChat account. Soon, the volunteers received this significant reply letter from Xi. This is a holiday memory that will remain unforgettable for youths in Xinjiang and across the country, volunteer Wang Yizhi told the Global Times. "Every single word in the letter conveys the expectations and trust that the Chinese leader has placed in our generation," said fellow volunteer Yan Zefeng. "Serving where the nation needs them most - this sentence reaffirmed that our original choice was the right one." Two years ago, when Gao Chao learned he had been assigned to teach at Xieyite Primary School, he knew almost nothing about it. At the time, Gao Chao had just graduated from the Shanxi Datong University in North China's Shanxi. Upon arriving in Xinjiang region, Gao Chao stood at the front of the classroom for the first time. Before her sat a second-grade class, the students neatly seated at their desks, eyes wide with curiosity. Gao Chao set a simple goal for herself: To teach each lesson well. She noticed that the herders' children struggled to understand common math problems using examples like "getting on and off the bus." So she localized the content, turning them into sheep-counting problems: "There were a certain number of sheep in the pen, some were let out in the morning, and some came back in the evening. How many are there now?" As a new teacher, Gao Chao realized how much she needed to learn. She kept refining his course plans, watching expert teaching videos online, and gradually, she grew into a capable and committed educator. In addition to academic improvement, the arrival of volunteers has also broadened the students' horizons. Gao Shuxian, a young woman also from Shanxi, joined Xieyite Primary School in 2023. At first, she discovered that most students had never traveled farther than Kashi city. Their exposure to the outside world was minimal. From then on, during every school break, Gao Shuxian would take photos and videos on her journey home to share with her students. Moreover, in August 2024, with the help of sponsorship, she and three other teachers took 12 students from the school on a study tour to Beijing. For many of the children, it was their first time leaving the remote region - and their first glimpse of the wider world. Dilizhada's most vivid memory was visiting Peking University, where she saw students radiating with confidence. "I used to think my life would be like that of my parents - living in the mountains forever. But after this trip, I realized college life is full of experiences. If I study hard now, I will have more choices in the future," she said. Heart-to-heart experience In the process of rooting themselves in the borderland primary school, these volunteers have also formed deep bonds with the children and their families, embodying the spirit of ethnic unity. Nuerbiye, a native of Korla city in central Xinjiang, came to Xieyite Primary School in 2022 after graduating from the Xinjiang Agricultural University. As a member of the Uygur ethnic group, she understands the importance of mastering Putonghua, China's national language. "Helping the children learn Putonghua well means they will be able to communicate no matter where they go in the future," she said. To support the students' language learning, Nuerbiye and other volunteers bought storybooks to encourage reading and used their spare time to teach the children to recite ancient Chinese poems. After nearly three years of effort, the students at Xieyite Primary School can now speak fluent Putonghua. Nuerbiye's dedication has won the appreciation of both students and parents. One parent even gave her a traditional Kirgiz dress during a home visit so I could experience local culture. In return, she gave the family a traditional Uygur Atlas fabric as a gift. "Since we arrived, teachers and students of different ethnic groups have lived and worked together in harmony." Yan, another volunteer teacher at the school, is known among the students as their warm-hearted "big brother." He carefully observes the children's learning habits and pays regular home visits, always quick to notice their needs. "It's important to understand what's going on inside their hearts." One mischievous boy shared that he had once been mocked by classmates because of his parents' divorce. He was in low spirits until Yan noticed he had not spoken all day. Yan quietly organized a themed class meeting on "how to get along with classmates," encouraging mutual support and empathy. Yan also asked students to write down their wish lists: Pens, notebooks, dictionaries, gloves… "Their wishes are so simple," he said. "One student even wrote, 'I hope my teacher stays healthy and happy.'" Yan admitted that seeing such pure hopes made it hard for him to ever let them down. The school's nearly 300 students are mostly the children of border patrollers. "Seeing how hard these families work to guard the border, I always feel like I haven't done enough," Yan told the Global Times. In his letter, Xi noted that more young people have chosen to serve as volunteers in the country's western regions and rural areas over the years, demonstrating their spirit of dedication and sense of responsibility. He urged the young people to stand firm in their ideals and convictions, cultivate patriotism, develop outstanding skills, and work hard to contribute to Chinese modernization. Since 2003, the "Go West" program has attracted over 540,000 college graduates and post-graduates engaging in voluntary service at more than 2,000 county-level areas, according to the CYLC, Xinhua reported in July 2024. For Nuerbiye, as she spent more time with her students, she found that the children had grown attached to her - and she to them. She has since renewed her volunteer contract twice. "This July will mark the end of my three-year maximum term. No matter how hard it is to part, I will have to leave. But more people will come to take my place," she said. This article first appeared in the Global Times: https://www.globaltimes.cn/page/202505/1333524.shtml Company: Global Times Contact Person: Anna Li Email: editor@globaltimes.com.cn Website: https://globaltimes.cn City: Beijing Disclaimer:This press release may contain forward-looking statements. Forward-looking statements describe future expectations, plans, results, or strategies (including product offerings, regulatory plans and business plans) and may change without notice. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements. The post Global Times: Xi’s reply letter to young volunteers in West China highlights their role in boosting education, fostering ethnic unity appeared first on ForexTV.

The GBP/USD weekly forecast is optimistic after the US-UK trade deal. Some BoE policymakers were not ready to cut interest rates. The dollar had a solid week due to optimism about easing trade tensions. The GBP/USD weekly forecast is optimistic, as the US-UK trade deal alleviates concerns about growth in Britain. Ups and downs of… […] The post GBP/USD Weekly Forecast: Trade Deal Calms UK Growth Fears appeared first on ForexTV.

The AUD/USD weekly forecast shows rising dollar demand. The Fed kept rates unchanged as expected. A trade deal between the US and the UK eased trade war fears. The AUD/USD weekly forecast shows rising dollar demand as market participants hope for a US-China trade deal. Ups and downs of AUD/USD  The AUD/USD pair had a… […] The post AUD/USD Weekly Forecast: US-China Deal Hopes Drive up Dollar appeared first on ForexTV.

European stocks experienced modest gains on Tuesday, with the STOXX 50 and STOXX 600 each rising by 0.1%. Investors were primarily focused on corporate earnings, while also anticipating significant developments such as tomorrow’s decision on monetary policy from the Federal Reserve. Market attention remained on international trade discussions, particularly those between the US and various Asian countries. Among notable earnings reports, Continental shares surged approximately 4% after the company recorded its highest sales in four years. Vestas saw a 6% increase, buoyed by a return to profitability in the first quarter, and Hugo Boss climbed nearly 7% following strong revenue results. Conversely, Philips fell by 1.8% due to a downgraded profitability forecast, while Covestro slipped 0.2% after amending its full-year earnings expectations. Additionally, Deliveroo rose by 2% in response to US-based DoorDash’s agreement to acquire the British firm for nearly £2.9 billion. Meanwhile, BP saw a rise of about 2.8% following reports of Shell evaluating its competitor, though Shell itself experienced a 1% decline. The material has been provided by InstaForex Company - www.instaforex.com The post European Stocks Edge Up, Earnings in Focus appeared first on ForexTV.

The Shanghai Composite Index saw a significant rise of 1.13%, ending at 3,316, while the Shenzhen Component Index soared by 1.84% to reach 10,082 in Tuesday's post-holiday session. The rally led to mainland stocks achieving their highest levels in a month, driven by renewed optimism regarding a potential US-China trade agreement. Last Friday, Beijing expressed readiness to engage in trade discussions with Washington, on the condition that the US first withdraw its unilateral tariffs as a sign of goodwill. Meanwhile, US President Donald Trump slightly dampened expectations by clarifying he has no plans to converse with Chinese President Xi Jinping within the week, though he did not rule out the possibility of reducing the prevailing 145% tariff on Chinese goods. On the economic landscape, China's services sector displayed some vulnerability, with data from April indicating growth had slowed to its weakest pace in seven months, impacted by trade disruptions affecting new business orders. In the equity market, technology stocks were at the forefront, with Talkweb Information climbing 5%, Shijiazhuang Changshan rising 10%, and Jiangsu Hoperun advancing by 8.7%. The material has been provided by InstaForex Company - www.instaforex.com The post China Stocks Gain on US-China Trade Optimism appeared first on ForexTV.

In April 2025, the S&P Global South Africa PMI increased to 50.0, up from 48.3 in March, marking a stabilization after experiencing four months of contraction. This improvement was primarily driven by modest recoveries in output, new orders, and employment, with several companies attributing this to increased demand and successful marketing strategies. Growth was predominantly seen in the services sector, whereas the industrial sector experienced a decline in production. A significant development was the enhancement of supplier delivery times for the first time since mid-2023, facilitated by reduced congestion at Durban's port. In response to the easing of supply chain issues, purchasing activity increased, although inventory levels experienced a slight drop. On the pricing front, there was a sharp acceleration in input cost inflation, reaching its highest in eight months, influenced by the depreciation of the rand and rising import prices. This led companies to increase their selling prices after a brief one-month pause. Looking forward, business expectations have slightly weakened, with sentiment hitting its second-lowest point in 19 months due to ongoing political and economic uncertainties. Nonetheless, 40% of companies remain optimistic about future output. The material has been provided by InstaForex Company - www.instaforex.com The post South Africa Private Sector Stabilizes in April appeared first on ForexTV.

For the first time since February, South Africa's manufacturing sector shows signs of expansion. According to the latest S&P Global Manufacturing PMI data released on May 6, 2025, the index rose to 50.0 in April, up from 48.3 in February 2025. This climb marks a vital movement as it crosses the crucial 50.0 threshold, indicating a shift from contraction to growth. The rise in the PMI highlights a resilient recovery in the South African manufacturing industry, likely driven by increased domestic demand and improved supply chain conditions. As businesses regain momentum, there is optimism for sustained growth, which could significantly contribute to the country's economic stability and job creation in the upcoming months. Market analysts credit this positive change to targeted governmental policies aimed at boosting manufacturing output along with a strengthening trade environment. The latest PMI data will be watched closely as a key indicator of the country's economic health, gauging potential impacts on investment and international trade partnerships. The material has been provided by InstaForex Company - www.instaforex.com The post South Africa’s Manufacturing Sector Returns to Growth as PMI Hits 50.0 appeared first on ForexTV.